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1. INTRODUCTION 
ORAL DRUG DELIVERY SYSTEM
1 
        A drug can be administered through various routes to produce prompt pharmacological 
effect. An oral delivery is considered as most favoured route of delivery in the pharmaceutical 
industry. 
This is due to following reasons: 
 Oral route is most convenient and uncomplicated 
 Ease of administration and safe 
 Improved patient compliance 
 Cost-effective 
Oral solid dosage forms such as tablets and capsules have been formulated and developed 
nowadays since they are the most effective routes of administration of a new drug. 
Nevertheless, it is probable that at least 90% of all drugs used to produce systemic effects are 
administered by the oral route. Tablets and capsules represent unit dosage forms in which one 
usual dose of the drug has been accurately placed. 
TABLETS 
        Tablet is defined as a compressed solid dosage form containing medicaments with or 
without excipients. They vary in shape and different greatly in size and weight, depending on 
amount of medicinal substance and the intended mode of administration. Tablet may be coated 
or uncoated, consist of one or more active substances with or without excipients such as 
diluents, binders, disintegrating agent, glidants, lubricants, substances capable of modifying the 
behaviour of the preparation indigestive tract, colouring matter authorized by the component 
authority and flavouring substances. It is the most popular dosage form and 70% of the total 
medicines are dispensed in the form of  tablet. 
ADVANTAGES
2 
 They are the unit dosage form and offer the greatest capabilities of all oral    dosage 
form for the greatest precision and least content variability. 
 Low cost among all oral dosage forms. 
 They are the easiest and cheapest to package and ship. 
 Product identification requires no additional processing steps when employing 
embossed or monogrammed punch face. 
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 Provides greatest ease of swallowing with the least tendency for hang up above the 
stomach, especially when provided the tablet disintegration is not excessively rapid. 
 They lend themselves to certain special release profile products E.g. enteric coated or 
delayed release profiles. 
 Easy large scale production than other oral dosage forms. 
 They have the best combined properties of chemical, mechanical and microbiological 
stability among all the oral dosage forms. 
 The emergency supplies of the drug can be conveniently carried by the patient. 
DISADVANTAGES:  
 Some drugs resist compression into dense compacts, owing to their amorphous nature 
or flocculent, low density character.  
 Drugs with poor wetting, slow dissolution properties, intermediate to large dosages, 
optimum absorption high in the gastro intestinal tract or any combination of this 
features may be difficult or impossible to formulate and manufacture as tablet that will 
still provide adequate or full drug bioavailability.  
 Bitter tasting drugs, drugs with an objectionable odour or drugs that are sensitive to 
oxygen or atmospheric moisture may require encapsulation or entrapment prior to 
compression, or the tablets may require coating. In such cases, the capsules may offer 
the best and lowest cost approach. 
TYPES OF TABLET: 
Tablets are divided into classes based on their route of administration and their 
function. 
1. TABLETS ADMINISTERED ORALLY: 
A. COMPRESSED TABLETS 
 Sugar coated tablets 
 Film coated tablets 
 Enteric coated tablets 
 Chewable tablets 
 Controlled release tablets 
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B. MULTIPLE COMPRESSED TABLETS 
 Layered tablets 
 Press coated tablets 
C. TABLETS ADMINISTERED IN ORAL CAVITY 
 Buccal and sublingual tablets 
 Lozenges and troches 
 Dental cores 
2. TABLETS ADMINTERED VIA OTHER ROUTES: 
 Implants 
 Compressed suppositories or inserts 
 Vaginal tablets 
3. TABLETS ADMINISTERED IN SOLUTION FORM 
 Effervescent tablets 
 Dispensing tablets 
 Hypodermic tablets 
 Tablet triturates 
LAYER  TABLETS
3
 
Layer tablets are composed of two or three layers of granulation compressed together. 
As the edges of each layer are exposed  they have the appearance of a sandwich. This dosage 
form has the advantage of separating two incompatible substances with an inert barrier 
between them. It makes possible sustained-release preparations with the immediate-release 
quantity in one layer and the slow release portion in the second. A third layer with an 
intermediate release might be added. 
Multi-layer tablet dosage forms are designed for variety of reasons which are as 
follows:  
 To control the delivery rate of either single or two different active pharmaceutical 
ingredients.  
 To separate incompatible active pharmaceutical ingredients from each other to control 
the release of active pharmaceutical ingredient from one layer by utilizing the 
Introduction 
 
Department of Pharmaceutics, Madras Medical College. Page 4 
 
functional property of the other layer such as, different active pharmaceutical 
ingredients, to prolong the drug product life cycle.  
 To modify the total surface area available for active pharmaceutical ingredients layer 
either by sandwiching with one or two inactive layers in order to achieve 
swellable/erodible barriers for modified release.  
 To fabricate novel drug delivery systems such as chewing device, buccal / 
mucoadhesive delivery systems and floating tablets for gastro-retentive drug delivery  
BILAYER TABLETS  
Bilayer tablets are composed of two layers of granulation compressed together. Two-
layer tablets require fewer materials than compression-coated tablets weigh less and may be 
thinner. Monograms and other distinctive markings may be impressed in the surfaces of the 
multilayer tablets.  
Coloring the separate layers provides many possibilities for unique tablet identity. 
Separation of the layers prior to assay may simplify the analytical work. Since there is no 
transfer to a second set of punches and dies, as with the dry-coating machine, odd shapes (such 
as triangles, squares, and ovals) present no operating problems except for those common to 
keyed tooling Several pharmaceutical companies are currently developing bilayer tablets, for a 
variety of reasons viz. patent extension, therapeutic, marketing to name a few.  
ADVANTAGES: 
 Ability to combine different release rate such as IR and CR in the same tablet for 
chronic conditions requiring the repeated dosing. 
 Improves patient compliance 
 Prolong duration of action 
 Better plasma drug level can be achieved 
 Retain potency and ensure dose accuracy 
 Maintain physical and chemical stability 
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CHALLENGES IN BILAYER MANUFACTURING  
Conceptually, bilayer tablets can be seen as two single-layer tablets compressed into one. 
In practice, there are some manufacturing challenges.  
 Delamination:  
Tablet falls apart when the two halves of the tablet do not bond completely. The two 
granulations should adhere when compressed.  
 Cross-contamination:  
When the granulation of the first layer intermingles with the granulation of the second 
layer or vice versa, cross-contamination occurs. It may conquer the very purpose of the 
bilayer tablet. Proper dust collection goes a long way toward preventing cross 
contamination. 
 Production Yields:  
To prevent cross contamination, dust collection is required which leads to losses.Thus, 
bilayer tablets have lower yields than single-layer tablets.  
 Cost:  
    Bilayer tableting is more expensive than single-layer tableting for several reasons: 
 The tablet press costs more.  
 The press generally runs more slowly in bilayer mode.  
 Development of two compatible granulations is must, which means more time 
spent    on  formulation development, analysis and validation 
These factors, if not well controlled/optimized, in one way or another will impact the 
bilayer compression per se and the quality attributes of the bilayer tablets (sufficient 
mechanical strength to maintain its integrity and individual layer weight control). Therefore, it 
is critical to obtain an insight into the root causes to enable design of a robust product and 
process. 
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QUALITY AND GMP REQUIREMENTS: 
To produce a quality bilayer tablet  in a validated and GMP manner, it is important that the 
selected press is capable of:  
 Preventing capping and separation of the two individual layers that constitute the 
bilayer tablets. 
 Providing sufficient tablet hardness.  
 Preventing cross -contamination between the two layers. 
 Producin a clear visual separation between the two layers.  
 High yield accurate and individual weight control of the two layers. 
APPLICATIONS  
 Bi-layer tablet is suitable for sequential release of two drugs in combination  
 Separate two incompatible substances. 
 Promoting patient convenience and compliance. 
 Bilayer tablet is improved beneficial technology to overcome the short coming of the 
single     layered tablet.  
 Bilayer tablets are used to deliver the loading dose and sustained dose of the same or 
different drugs.  
 Bilayer tablets are used for bilayer floating tablets in which one layer is floating layer 
and another one is immediate release layer of the drug.  
 
CONTROLLED DRUG DELIVERY SYSTEMS (CDDS)
4 
 Controlled release drug delivery system was designed to deliver for a prolonged 
period. Safe and effective blood levels are maintained for longer period as the system continues 
to deliver the drug. Controlled drug delivery usually results in constant blood levels of the drug 
as compared to the uncontrolled fluctuations observed when multiple doses of quick releasing 
conventional dosage forms are administered to a patient. 
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Advantages 
Controlled release products offer many potential benefits over conventional dosage 
formulations, they are 
 Sustained blood levels 
 Dosage frequency reduction 
 Improve patient compliance 
 Improve efficiency in treatment 
 Economy i.e. reduction in health care costs etc. 
Disadvantages 
 Controlled release products contain a higher drug load and thus any loss of integrity of 
the release characteristics of the dosage form has potential problems. 
 The larger size of sustained release sustained release products may cause difficulties in        
ingestion or transit through the gut. 
 Sustained release products may cause decreased systemic bioavailability in  comparison 
to conventional dosage forms, which may be due to incomplete release, increased first 
pass metabolism, increased instability, insufficient residence time for complete release, 
site specific absorption, pH dependent stability etc. 
 Possibility of dose dumping due to food, physiologic or formulation variables or 
chewing or grinding of oral formulations by the patient and thus increased risk of 
toxicity. 
 
GASTRORETENTIVE DRUG DELIVERY SYSTEMS
5,6 
Dosage form with a prolonged gastric residence and controlled drug delivery are called 
as GRDDS. Oral controlled release dosage forms are developed due to their therapeutic 
advantages such as patient compliance, ease of administration and flexibility in formulation. 
However this approach has several physiological difficulties such as inability to locate the 
dosage form at the desired region of the gastrointestinal tract (GIT) due to variable gastric 
emptying time. The gastric emptying time in human normally ranges from 2-3 hours through 
which the major absorption zone (stomach and upper part of intestine) passes through that so 
the dosage form can result in incomplete drug absorption from the delivery system and leading 
to reduced efficacy of the administered dose. Therefore the control of placement of a drug 
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delivery system in a specific region of the GIT offers greater advantage. The drugs 
characterized by a narrow absorption window in the GIT or drugs with a stability problem in 
the intestine can be benefitted by this approach. These have led to the development of a unique 
oral controlled release dosage form with gastro retentive properties. 
After oral administration, such a dosage form would be retained in the stomach and 
release the drug there in a controlled and prolonged manner, so that the drug could be supplied 
continuously to its absorption sites in the upper GIT. 
 
ANATOMICAL AND MECHANICAL ASPECTS OF  STOMACH
7 
A basic understanding of the anatomical and mechanical aspects of the stomach is 
needed for a pharmaceutical formulator to develop successful gastro retentive formulation.The 
stomach is divided into 4 regions are the cardia, fundus, body and pylorus. 
 
 
                              Fig. 1:Anatomical representation of the stomach 
 
          The process of gastric emptying occurs both during fasting and fed states. The pattern of 
motility differs markedly in the two states. In the fasted state it is characterized by an inter-
digestive series of electrical events which cycle both through the stomach and small intestine 
for every 2-3 hours. 
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Gastric emptying is divided into 4 phases are as following: 
This is called the inter-digestive myoelectric cycle or migrating myoelectric cycle 
(MMC) which is further divided into following 4 phases as described by Wilson and 
Washington. 
 Phase I(Basel phase) lasts from 30 to 60 minutes with rare contractions.  
 Phase II (Pre burst phase) lasts for 20 to 40 minutes with intermittent action potential 
and contractions.  
 Phase III (Burst phase) lasts for 10 to 20 minutes. It includes intense and regular 
contractions for short period. It is due to this wave that all the undigested materials 
swept out of the stomach down to the small intestine. It is also known as the 
housekeeper wave.  
 Phase IV lasts for 0 to 5 minutes and occurs between phases III and 1of 2 consecutive 
cycles.  
 
                                            
                              Fig.2: Motility patterns of the GIT in the fasted state 
Drug candidates suitable for gastro-retention 
 Drugs having poor colonic absorption but get rapidly absorbed in the upper parts of the 
GIT are the suitable candidates to be employed for gastro-retention. 
 Drugs with  narrow absorption window .e.g Levodopa and Riboflavin. 
 Drugs that get primarily absorbed in stomach and upper part of stomach e.g. 
Cinnarizine, Chlordiazepoxide and Calcium supplements. 
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 Drugs having the property of degrading in stomach e.g. Metronidazole and Ranitidine 
 Drugs that disturb the normal colonic bacteria e.g Amoxicillin Trihydrate 
 Drugs acting locally in the stomach e.g .Antacids and Misoprostol . 
 Drugs that exhibit low solubility at high ph values e.g. Diazepam, Chlorodiazepam and 
Verapamil HCl. 
Factors affecting the Gastro retentive system
6 
The Gastric Retention Time (GRT) of dosage form is controlled by several factors that 
affect their efficacy as a gastro retentive system. 
Density 
Density of the dosage form should be less than the gastric contents (1.004 gm/ml). 
Size 
Dosage form unit with a diameter of more than 7.5 mm are reported to have an 
increased GRT competed to with those with a diameter of 9.9 mm. 
Shape of dosage form 
Tetrahedron and ring-shaped devices with a flexural modulus of 48 and 22.5 
Pounds per Square Inch (PSI) are reported to have better GRT. 90 % to 100 % retention at 24 
hours compared with other shapes. 
Single or multiple unit formulation 
Multiple unit formulations show a more predictable due to failure of units, allow co-
administration of units with different release profiles or containing incompatible substances 
and permit a larger margin of safety against dosage form failure compared with single unit 
dosage forms. 
Fed or unfed state: 
Under fasting conditions the GI motility is characterized by periods of strong motor 
activity or the MMC that occurs every 1.5 to 2 hours. The MMC sweeps undigested material 
from the stomach and if the timing of administration of the formulation coincides with that of 
the MMC, the GRT of the unit can be expected to be very short. However in the fed state 
MMC is delayed and GRT is considerably longer. 
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Nature of meal 
  Feeding of indigestible polymers or fatty acid salts can change the motility pattern of 
the stomach to a fed state, thus decreasing the gastric emptying rate and prolonging drug 
release 
Caloric content 
GRT can be increased by four to 10 hours with a meal that is high in proteins and fats. 
Frequency of feed 
The GRT can increase by over 400 minutes when successive meals are given compared 
with a single meal due to the low frequency of MMC. 
Gender 
Mean ambulatory GRT in males (3.4±0.4 hours) is less compared with their age and 
race-matched female counter parts (4.6±1.2 hours), regardless of the weight, height and body 
surface. 
Age 
Elderly people, especially those over 70 years have a significantly longer GRT. 
Posture 
GRT can vary between supine and upright ambulatory states of the patient. 
Disease states 
Diabetes, Crohn’s disease etc., 
Concomitant drug administration 
Anticholinergic like Atropine and Propantheline, Opiates like Codeine and Prokinetic agents 
like Metoclopramide and Cisapride. 
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Fig. 3: Approaches to gastric retention 
FLOATING DRUG DELIVERY SYSTEMS (FDDS)
7 
Floating drug delivery system or hydro dynamically balanced systems have a bulk 
density lower than gastric contents and thus remain buoyant in the stomach without affecting 
the gastric emptying rate for a prolonged period of time while the system is floating on the 
gastric contents the drug is released slowly at a desired rate from the system. After the release 
of the drug, the residual system is emptied from the stomach. This results increase in the GRT 
and a better control of fluctuations in plasma drug concentrations. However, besides a minimal 
gastric content needed to allow the proper achievement of the buoyancy retention principle, a 
minimal level of floating force (F) is also required to keep the dosage form reliably buoyant on 
the surface of the meal. 
Types of floating drug delivery system  
Based on the mechanism of buoyancy, two distinctly different technologies have been 
utilized in the development of FDDS. 
I. Non-Effervescent FDDS 
The Non-effervescent FDDS is based on mechanism of swelling of polymer or 
bioadhesion to mucosal layer in GI tract. The most commonly used excipients in 
noneffervescent FDDS are gel forming or highly swellable cellulose type hydrocolloids, 
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hydrophilic gums, polysaccharides and matrix forming materials such as polycarbonate, 
polyacrylate, polymethacrylate, polystyrene as well as bioadhesive polymers such as Chitosan 
and Carbopol. 
The various types of this system are as: 
1. Colloidal Gel Barrier Systems 
Hydro-dynamically balanced system (HBS) of this type contains drug with gel forming 
or swellable cellulose type hydrocolloids, polysaccharides and matrix forming polymers. They 
help in prolonging the GI residence time and maximize drug reaching its absorption site in the 
solution form ready for absorption. These systems incorporate high levels (20 to 75 % w/w) of 
one or more gel forming highly swellable cellulose type hydrocolloids e.g. Hydroxy ethyl 
cellulose, Hydroxy propyl cellulose, Hydroxy propylmethyl cellulose, Sodium carboxy methyl 
cellulose incorporated either in tablets or capsules. 
A. Single Layer Floating Tablets: 
They are formulated by intimate mixing of drug with a gel-forming hydrocolloid,which 
swells in contact with gastric fluid and maintains bulk density of less than unity. They are 
formulated by intimate mixing of drug with low-density enteric materials such as HPMC. 
B. Bi-layer Floating Tablets: 
A bi-layer tablet contain two layer one immediate release layer which releases initial 
dose from system while the another sustained release layer absorbs gastric fluid, forming an 
impermeable colloidal gel barrier on its surface and maintain a bulk density of less than unity 
and thereby it remains buoyant in the stomach. 
            
Fig. 4 :Intragastric floating tablet. 
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2. Micro porous compartment system 
This technology is comprised of encapsulation of a drug reservoir inside a micro porous 
compartment with pores along its top and bottom surfaces. The peripheral walls of the drug 
reservoir compartment are completely sealed to prevent any direct contact of gastric mucosal 
surface with undissolved drug. In stomach, the floatation chamber containing entrapped air 
causes the delivery system to float over the gastric contents. Gastric fluid enters through the 
pores, dissolves the drug and carries the dissolved drug for continuous transport across the 
Intestine for absorption. 
 
           
               
Fig. 5:  Micro porous intra-gastric floating drug delivery device 
3. Alginate Beads 
            Multi-unit floating dosage forms were developed from freeze dried calcium 
alginate.Spherical beads of approximately 2.5 mm diameter can be prepared by dropping 
sodium alginate solution into aqueous solution of calcium chloride, causing precipitation of 
calcium alginate leading to formation of porous system, which can maintain a floating force for 
over12 hours. When compared with solid beads, which gave a short residence time of 1 hour, 
and these floating beads gave a prolonged residence time of more than 5.5 hours. 
4. Hollow Microspheres 
             Hollow microspheres (Microballoons), loaded with drug in their outer polymer shells 
are prepared by a novel emulsion-solvent diffusion method. The ethanol: dichloromethane 
solution of the drug and an enteric acrylic polymer is poured into an agitated aqueous solution 
of PVA that is thermally controlled at 40 °C. The gas phase generated in dispersed polymer 
droplet by evaporation of dichloromethane forms an internal cavity in microsphere of polymer 
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with drug. The Micro balloons float continuously over the surface of acidic dissolution media 
containing surfactant for more than 12 hours. 
 
Fig.6: Mechanism of micro balloon formation by emulsion-solvent diffusion Method. 
II. Effervescent FDDS
5 
           A drug delivery system can be made to float in the stomach by incorporating a floating 
chamber, which may be filled with vacuum, air or inert gas. The gas in floatingchamber can be 
introduced either by volatilization of an organic solvent or by effervescentreaction between 
organic acids and bicarbonate salts. 
 
Fig.7: Floating pills: The penetration of water into effervescent layer leads to a CO2 
generation and makes the system to float. 
A. Volatile liquid containing system 
             The GRT of a drug delivery system can be sustained by incorporating an inflatable 
chamber, which contains a liquid e.g. ether, cyclopentane, that gasifies at body temperature to 
cause the inflatation of the chamber in the stomach. The device may also consist of a 
bioerodible plug made up of Poly vinyl alcohol, Polyethylene etc. that gradually dissolves 
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causing the inflatable chamber to release gas and collapse after a predetermined time to permit 
the spontaneous ejection of the inflatable systems from the stomach. 
a. Inflatable gastrointestinal delivery systems 
             In these systems an inflatable chamber is incorporated, which contains liquid that 
gasifies at body temperature to cause the chamber to inflate in the stomach. The inflatable 
chamber automatically inflates and retains the drug reservoir compartment in floating position. 
The drug continuously released from the reservoir into the gastric fluid. 
 
                    
Fig.8: Inflatable gastrointestinal delivery system 
b. Intragastric osmotically controlled drug delivery system 
It is comprised of an osmotic pressure controlled drug delivery device and an inflatable 
floating support in a biodegradable capsule. In the stomach capsule quickly disintegrates to 
release the intragastric osmotically controlled drug delivery device. The inflatable support 
inside forms a deformable hollow polymeric bag that contains a liquid that gasifies at body 
temperature to inflate the bag. The osmotic pressure controlled drug delivery device consists of 
two components; drug reservoir compartment and an osmotically active compartment. 
The drug reservoir compartment is enclosed by a pressure responsive collapsible bag, 
which is impermeable to vapour and liquid and has a drug delivery orifice. The osmotically 
active compartment contains an osmotically active salt and is enclosed within a semipermeable 
housing. In the stomach the water in the GI fluid is continuously absorbed through the 
semipermeable membrane into osmotically active compartment to dissolve the osmotically 
active salt. An osmotic pressure is thus created which acts on the collapsible bagand turns in 
forces the drug reservoir compartment to reduce its volume and activate the drug reservoir 
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compartment to reduce its volume and activate the drug release in solution form through the 
delivery orifice. The floating support is also made to contain a bioerodible plug that erodes 
after a predetermined time to deflate the support. The deflated drug delivery system is then 
emptied from the stomach. 
 
                               
Fig.9: Intragastric osmotically controlled drug delivery system 
B. Gas-generating Systems: 
             These buoyant delivery systems utilize effervescent reactions between 
carbonate/bicarbonate salts and citric/tartaric acid to liberate CO2, which gets entrapped in the 
gellified hydrocolloid layer of the systems thus decreasing its specific gravity and making it to 
float over chyme. 
1.8. MECHANISM OF FLOATING SYSTEMS
8 
            Floating drug delivery systems (FDDS) have bulk density lesser than gastric fluid , so 
they remain buoyant in the stomach without affecting the gastric emptying rate for a prolonged 
period of time, while the system is floating on the gastric contents the drug released slowly at 
the desired rate from the system as shown in Fig 9. However, besides a minimal gastric content 
needed to allow the proper achievement of the buoyancy retention principle, a minimal level of 
floating force (F) is also required to keep the dosage form reliably buoyant on the surface of 
the meal. To measure the floating force kinetics, a novel apparatus for determination of 
resultant weight has been reported. The apparatus operates by measuring continuously the 
force equivalent to F (as function of time) that is required to maintain the submerged object. 
The object floats better if F is on the higher positive side as shown in fig10. This apparatus 
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helps in optimizing FDDS with respect to stability and durability of floating force proceed in 
order to prevent the drawbacks of unforeseeable intragastric buoyancy capability variations. 
F =F Buoyancy-F Gravity=(Df-Ds) gv 
Where, 
                  F = total vertical force 
                  Df = fluid density 
                  Ds =object density 
                  V = volume 
                   g =acceleration due to gravity 
 
                        
Fig.10: Mechanism of floating systems 
 NON-FLOATING SYSTEMS 
             These are another class of gastro retentive drug delivery systems which do not float but 
remain in the stomach for a prolonged time period14. These systems are formulated by any of 
the following approaches,  
 Bioadhesive systems: 
       These types of systems adhere to the biological membrane (mucosa) of the stomach and 
maintain intimate contact with the membrane for a longer time and hence retains in stomach 
for its prolonged release. These systems are formulated using bioadhesive polymers which can 
adhere to epithelial surface in the stomach. Some of the most promising excipients that have 
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been used commonly in these systems include polycarbophil, carbopol, lecithins,chitosan, 
CMC and gliadin, etc. 
 Swelling systems: 
      These are the type of non-floating gastro retentive drug delivery system which enters 
stomach swells (due to presence of swellable polymers) to an extent that cannot pass through 
the pyloric sphincter leading to its retention in the stomach. 
 High density systems: 
       These systems possess density greater than the gastric fluids due to which the system sinks 
to the bottom and remains in the stomach. These are formulated by coating drug on heavy inert 
materials like zinc oxide, titanium dioxide, iron powder etc... 
 Expandable systems: 
        These systems are capable of expanding and retain in the stomach for longer 
periods.These are usually formulated as a capsule containing dosage form in folded and 
compact form. After being exposed to stomach environment, capsule shell disintegrates and 
dosage form expands preventing its exit through the stomach. By using a suitable polymer, 
sustained and controlled drug delivery can be achieved. 
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S. Mohideen et al.,
9 
developed a bilayer tablet  consisting of Atorvastatin calcium as 
an immediate release layer and Metformin hydrochloride as a sustained release layer. 
Granules of different formulations of  both the drugs were evaluated for bulk density, 
tapped density, compressibility index and Hausner’s ratio. The prepared bilayer 
tablets were evaluated for weight variation, thickness, hardness, friability, drug 
content and in vitro drug release. The in vitro release profile showed the desired 
biphasic behavior. The Metformin hydrochloride released for more than 12 hrs, where 
as Atorvastatin calcium dissolved within 45 min.Bilayer tablet prepared from 
optimized formula (Trial 10) was found to be best suited method for fixed dose 
combination of  sustained release Metformin Hydrochloride and immediate release 
Atorvastatin calcium. 
 
Ajit Kulkarni and Manish Bhatia
10 
prepared the regioselective bilayer floating 
tablets of Atenolol and Lovastatin for biphasic release profile by direct compression 
technique.The bilayer floating tablets comprised of two layers, immediate release 
layer of Lovastatin and sustained release layer of Atenolol. The immediate release 
layer comprised of Sodium Starch Glycolate as a super disintegrant and the sustained 
release layer comprised of Hydroxy Propyl Methyl Cellulose (HPMC) K100M and 
Xanthan gum as the release retarding polymers. Sodium bicarbonate was used as a gas 
generating agent. All formulation floated for more than 12 hours and release 90% of 
Lovastatin within 30 min. roentgenography was carried out to study the in vivo 
buoyancy of the optimized formulation and it was found to be buoyant for 8 hours in 
stomach. 
 
Kotta kranthi kumaret al.,
11 
designed the concept of bilayered tablets containing 
Pioglitazone hydrochloride for immediate release using cross Povidone as super 
disintegrant and Metformin hydrochloride for sustained release using poly ethylene 
oxide (PEO-303) as matrix forming polymer. The tablets were evaluated for 
physicochemical properties. All the values are found to be satisfactory. In vitro 
release studies were carried out as per USP in pH 1.2 and phosphate buffer pH 6.8 
using the USP apparatus II. The release kinetics of Metformin hydrochloride was 
evaluated using the regression coefficient analysis. The formulated tablets (F5) shows 
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first order release and diffusion was the dominant mechanism of drug release. The 
polymer Polyethylene oxide (PEO- 303) had significant effect on the release of 
Metformin HCl matrix tablets (F5).Thus formulated bilayer tablets proved immediate 
release of Pioglitazone and Metformin HCl as sustained release over a period of 12 
hours. The stability studies and FT-IR studies were also indicating the absence of 
strong interactions between the components and suggesting drug-excipient 
compatibility in all the formulations examined.  
 
Patel Geeta M. et al.,
12 
developed and evaluated Atorvastatin calcium (ATC) & 
Metoprolol succinate (MP) in same dosage form. The regioselective tablets were 
prepared by direct compression. Polyox WSR N-60K and HPMC K100M was used as 
hydrophilic polymers. Effervescent was incorporated into the formulations to float the 
dosage form. The amount of polymer blends was optimized using 32 full factorial 
design. The swellings and in-vitro release were studied. Floating lag time and floating 
duration of prepared tablets was determined. All formulations floated for more than 
18-20 hrs. More than 90% of Atorvastatin calcium was released within 1 h.The 
stability study showed no significant change in appearance of tablets, floating 
characteristics and drug dissolution profile. 
 
Dey S et al.,
13 
formulation and evaluation of fixed-dose combination of bilayer 
gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol 
assustained-release. The objective of the study was to develop bilayer tablets of 
atorvastatin and atenolol that are characterized by initial fast-release of atorvastatin in 
the stomach and comply with the release requirements of sustained-release of 
atenolol. Atorvastatin contained in the fast-release layer showed an initial fast-release 
of more than60% of its drug content within 2 hours, followed by sustained release of 
the atenolol for aperiod of 12 hours. It concludes that the bilayer tablets of 
atorvastatin and atenolol can be successfully employed for the treatment of 
hypertension and hypercholesterolemia together through oral administration of single 
tablet. 
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PreetiKarwa et al.,
14
designed  bilayer tablet of Zolpidem Tartrate (ZT) for biphasic 
release and in vitro evaluation of the same. Bilayer tablets comprised two layers, i.e. 
immediate release and controlled release layer. The immediate release layer 
comprised croscarmellose sodium as a super disintegrant and the controlled release 
layer comprised HPMC K100M as the release retarding polymers. Direct compression 
method was used for formulation of the bilayer tablets. In vitro dissolution studies 
were carried out in a USP apparatus I, basket method. HPMC K100M extended the 
release of drug from the extended release layer for 6 hrs. FTIR studies revealed that 
there was no interaction between the drug and polymers used in the study. The release 
of Zolpidem Tartrate was found to follow a pattern of Korsmeyer-Peppas, with Quasi-
Fickian diffusion. Accelerated stability studies were carried out on the prepared 
tablets in accordance with ICH guidelines. There were no changes observed in 
physicochemical properties and drug release pattern of tablets. Biphasic drug release 
pattern was successfully achieved through the formulation of bilayer tablets in this 
study. 
 
Kulkarani et al.,
15  
prepared the floating bilayer tablets of Diltiazem hydrochloride 
and Lovastatin. Direct compression technique was employed for preparing bilayer 
tablets.Lovastatin was formulated as immediate release layer using sodium starch 
glycolate as super disintegrant and diltiazem hydrochloride was formulated as 
sustained release layer comprising of HPMC K4M and Xanthan gum as the release 
retarding polymers. Sodium bicarbonate was used as a gas generating agent. All the 
formulations released theLovastatin within 30 minutes. HPMC K4M and Xanthan 
gum sustained the release for 12hours. 
 
Prabhakar Shirse.,
16
formulated and evaluated the bilayered tablets containing 
Diclofenac Sodium in the sustained release (SR) portion and Ranitidine HCl in the 
immediate release (IR) portion in order to produce a single tablet containing two 
different classes of drugs.The sustained release layer of Diclofenac Sodium was 
prepared by using different grades of HPMC like, HPMC E15, HPMC K4M, K100M, 
and Ethyl Cellulose with cross carmellose along with other excipients like 
Magnesium stearate, Microcrystalline cellulose & PVP by wet granulation technique. 
The drug release study of Ranitidine HCl and Diclofenac Sodium were evaluated 
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using USP-XXII paddle type dissolution apparatus.The release rate of Ranitidine HCl 
was studied for 45 min using water as media and that of Diclofenac Sodium was 
studied for 2 hrs in 1.2pH buffer followed by 6 h in pH 6.8 phosphate buffer media 
using a developed HPLC method. 
 
Ankarao, A et al.,
17 
prepared the Buccoadhesive bilayer tablets of Metoprolol 
tartrate.Core tablet of metoprolol tartrate was prepared by direct compression 
technique using HPMC K4M, SCMC and Carbapol 934 as bioadhesive polymers to 
impart muco adhesion and ethyl cellulose to act as an impermeable backing layer. Six 
formulations containing the bioadhesive polymers were prepared. The formulation F2 
and F5 were optimized and obeyed zero order release kinetics with non-ficikan 
diffusion. 
 
Saad M. Majeed et al.,
18 
formulated a dual therapy of peptic ulcer containing 
antimicrobial agent amoxicillin and anti-secretory agent esomeprazole. Different 
formulas of 500 mg amoxicillin were prepared as sustained release layer by wet 
granulation method; similarly, different formulas of 20 mg esomeprazole in form of 
enteric coated pellets was prepared as extended release matrix layer by direct 
compression technique, using pH-independent hydrophilic Eudragit polymers (E-
RL100 and E-RSPM type) as matrix forming agent. The physical characteristics and 
release properties for compressed amoxicillin and esomeprazole matrix tablets were 
studied in addition the effect of polymer type, polymer concentration, polymer 
combination and ratio, effect of diluent type, binder type and method of preparation 
on the release of amoxicillin and esomeprazole from compressed matrix tablets.The 
results showed that formulas prepared with Hydroxy propyl methyl cellulose (HPMC 
K100M) and Xg in a ratio of 4:1 and PVP as binder was capable to retard the release 
of amoxicillin for 12 hours. 
 
Anup Kumar Chakraborty et al.,
19 
explained a new, simple, precise, rapid, and 
accurate reverse phase liquid chromatographic method for formulation containing 
Rosuvastatin Calcium as active pharmaceutical ingredient. A Phenomenex-C18 (250 
x 4.6mm) with a particle size of 10µ column was used with a mobile phase containing 
a mixture of Buffer: Acetonitrile in the ratio 55:45. The flow rate was 1.0ml/min and 
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effluents were monitored at 244nm and eluted at 6±0.5 min. The assay was validated 
for the parameters like accuracy, precision, robustness and system suitability 
parameters.The proposed method can be useful in the routine analysis for the 
determination, development and to validate a new High Performance Liquid 
Chromatographic method (HPLC) for such an analysis. 
 
M. Harikrishna et al.,
20 
developed a bilayer floating tablet for Atenelol and 
Carvedilol using direct compression method. Bilayer floating tablets were designed to 
prolong gastric retention time and increase the bioavailability of the drug. Bilayer 
floating tablets made up of two layers, immediate release layer and controlled release 
layer. Immediate release layer contains sodium starch glycolate as a super 
disintegrating agent and controlled layer contains carbapol934p grade polymers and 
Ethyl cellulose as controlled release polymers .Sodium bicarbonate is used as a gas 
generating agent. The tablets were evaluated for physico-chemical properties such as 
bulk density, tapped density, hausner’s ratio, hardness, thickness, friability, drug 
content, floating lag time, floating duration in vitro drug release by dissolution studies 
and stability studies . FT-IR studies revealed that there was no interaction between the 
drug and polymer used in the study. The optimized tablets B12 showed controlled and 
complete drug released 99.95% over a period of 24 hrs. And it follows zero order 
release and non-Fickian diffusion. 
 
Sreelatha. P et al.,
21
 developed sustained release tablets of Rosuvastatin to prolong 
release of time to increase in drug bioavailability.Tablets were prepared by direct 
compression technique using polymers HPMC K15,HPMC K50M and ethyl 
cellulose.Tablets were evaluated for their physical characteristics viz., hardness, 
thickness,friability,weight variation,drug content and floating properties. Gas 
generating agent plays an important role in floating lag time and drug release.The best 
formulation subjected for kinetic treatment.i.e. zero order, first order,pepas,Higuchi 
and Hixson crowell.  
 
M.M.Guptaet al.,
22
designed bilayer tablets of rosuvastatin and diltiazem 
hydrochloride to give conventional release of rosuvastatin calcium and sustained 
release of diltiazem hydrochloride. The conventional release layer comprised lactose 
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and micro crystalline cellulose as diluents (separately and in combined form) and the 
sustained release layer comprised HPMC K100M and ethyl cellulose (with different 
ratio of HPMC K100M and ethyl cellulose) as the release retarding polymers. Direct 
compression method was used for formulation of the bilayer tablets. Preformulation 
studies were performed prior to compression. The bilayer tablets were evaluated for 
weight variation, dimension, hardness, friability, drug content, and disintegration time 
and in vitro drug release using USP dissolution apparatus type II (paddle). More than 
90% of rosuvastatin calcium was released within 150 min. HPMC K100M and Ethyl 
cellulose sustained the release of diltiazem hydrochloride from the sustained release 
layer for 24 hour. After stability tests, degradation of both drugs were found but the 
drugs contents were found within the range.  
 
Amish V. Panchalet al.,
23
 established  mucoadhesive buccal device of Rosuvastatin 
Calcium(RC) in the form of bilayered tablet. The tablets were prepared using natural 
gums like Xanthan gum, Tamarid gum, Gellan gum and Chitosan as bioadhesive 
polymers to impart mucoadhesion as well as permeation enhancement property to the 
formulation. Ethyl cellulose & magnesium stearate were added to act as an 
impermeable backing layer which gives unidirectional buccal drug delivery. Buccal 
devices were evaluated for different parameters such as weight uniformity, content 
uniformity, thickness, hardness, surface pH, swelling index, ex vivo mucoadhesive 
strength, ex vivo mucoadhesive time, in vitro drug release, and in vitro drug 
permeation. The results of study revealed that the formulation containing a 
combination of polymers like chitosan and natural gums shows suitatble drug 
permeation rate as well as mucoadhesive strength. 
 
Mahathiyelugamet al.,
24
 formulated and evaluated floating microspheres of 
carvedilol. Floating microspheres were prepared by emulsion solvent diffusion 
method using ethanol and dichloromethane as solvents. Ethyl cellulose and HPMC K4 
M were used to prolong the release of the drug from microspheres. The prepared 
microspheres were subjected to various evaluatory studies. All the microspheres were 
found to have a size in the range of 20-40 μ and were nearly spherical in shape. 
Optimised batch F11 exhibited good buoyancy (73 ± 1.00 %) and sustained release 
(45.41 ± 0.13 % Cumulative drug dissolved) ( % CDD) compared to other 
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formulations. It was subjected to dissolution studies using USP type 1 apparatus and 
Rosette rice apparatus. Drug release data was compared with the release data obtained 
from marketed tablet Cardivas (Controlled Release) CR. The release kinetics obtained 
using Rosette Rice apparatus were good compared to USP type I apparatus. The 
release of the drug from microspheres and Cardivas CR followed non-fickian 
anamolous diffusion. 
 
A. Ankarao et al.,
25 
established mucoadhesive buccal tablets of 
carvedilol in the forms of bilayered tablets. The tablets were prepared using Hydroxy 
propyl methyl cellulose (HPMC K4M) and sodium carboxy methylcellulose (SCMC) 
andCarbopol-934 (CP) as bioadhesive polymers to impart mucoadhesion and ethyl 
cellulose (EC) to act as an impermeable backing layer. Buccal tablets were evaluated 
by different parameters such as weight uniformity, content uniformity, thickness, 
hardness, surface pH, swelling index, ex vivo mucoadhesive strength, in vitro drug 
release, and in vitro drug permeation. The mechanism of drug release was found to be 
non-Fickian diffusion (value of n between 0.5 and 1.0) for both the buccal tablets. 
 
M. Sujatha et al.,
26
 formulated the Carvedilol tablets by employing Hydrophilic 
polymers such as HPMC K15, Xanthan gum and Guar gum, Sodium bicarbonate is 
used as a gas generating agent through wet granulation technique. Among the 
formulations F1 to F9 the F6 formulation (HPMC K15 and Gaur gum 1:1 ratio) was 
optimized to get 93% drug release and prolonged the drug release for more than 
12hrs. The resulting formulations produced consistent hardness, uniformity in weight 
and low friability. The formulation with HPMC and Guar gum in the drug and 
polymer ratio has optimum floating lag time. The optimized formula F6 was fitted to 
various kinetic models and the result showed that F6 batch followed Zero order 
kinetics. The mechanism of drug release from F6 batch was Higuchi’s with non 
fickian diffusion pattern. These results indicate that the selected formulation was 
stable during the period of accelerated stability studies. 
 
P Gajula et al.,
27
 prepared buccoadhesive tablets of Rosuvastatin calcium by direct 
compression method using HPMC K4M, HPMC K15M and carbopol 974P as 
mucoadhesive polymers and evaluated for in vitro drug release, in vitro bioadhesion, 
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ex vivo residence time, swelling index, surface pH and ex vivo drug permeation. 
Fifteen formulations were developed with varying concentrations of polymers. 
Formulations from F1 to F5 were composed of HPMC K4M, F5 to F10 using HPMC 
K15M and F11 to F15 using carbopol 974. The ratio of drug and polymer were varied 
from 1:1 to 1:5 in F1 to F10 and 1:0.25 to 1:1.50 in F11 to F15. Formulation F3 
showed maximum release of the drug (97.83 ± 0.41%), and from the same 
formulation maximum drug has permeated (73.14 ± 0.13%) through porcine buccal 
membrane with a flux of 8.35 ± 0.291μg h-1cm-2, permeation coefficient of 1.34 ± 
0.05 cmh-1 and maximum bioadhesive force of 24.64±0.246 respectively. FTIR 
results showed no evidence of interaction between the drug and polymers. The results 
indicate that suitable bioadhesive buccal tablets with desired permeability could be 
prepared. 
 
Shinkar Dattatraya Manohar et al.,
28 
examined the release of carvedilol from 
various molecular weight fractions of gelucire solid dispersions. Solid dispersions of 
ratios of carvedilol were prepared in different molar ratios of drug : carrier by using 
solvent evaporation and melting methods. The physical mixture and solid dispersion 
(s) were characterized for drug-carrier interaction, drug content, solubility and 
dissolution rate. The release rate of carvedilol from the resulting complexes was 
determined from dissolution studies by use of USP dissolution apparatus 2 (paddle 
method). The physical state and drug: gelucire interaction of solid dispersions and 
physical mixtures were characterized by X-ray diffraction (XRD), Infra Red 
Spectroscopy (IR) and Differential Scanning Calorimetry (DSC). The dissolution rate 
of carvedilol was increased significantly in all of the solid dispersion systems 
compared to that of the pure drug and physical mixtures. The solid dispersion 
prepared in the molar ratio of 1:2 by the solvent evaporation method was found to 
have the fastest dissolution profile. 
 
Omar s. salihet al.,
29
 formulated and evaluated Rosuvastatin calcium  niosomes  
using non-ionic surfactants (Span 20,Span 60,span 80), cholesterol and lecithin in 
different ratios by film hydration method and evaluate the formulas in terms of assay 
of drug in each formula (entrapment efficiency) by HPLC, particle size, morphology, 
in-vitro drug release and ex-vivo permeation study. Scanning electron microscopy 
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(SEM) and transmission electron microscopy (TEM) were used for characterization of 
the selected formula. Fourier transform infrared (FTIR) was used for study of drug – 
excipients compatibilities. All formulas gave obvious morphology in the presence of 
cholesterol as a stabilizing agent, formula with span 60 had more entrapment 
efficiency than all other formulas, with slower release after 7 hours in vitro 
dissolution media, TEM results show vesicle size of F6 niosomal vesicle was 150nm 
in diameter.  
 
Sowjanya Polanki et al.,
30 
developed oral gastroretentive floating tablets of 
carvedilol, to prolong the gastric residence time and improves the bioavailability of 
the drug as well as its half life. All the precompression parameters of formulation 
blends of Carvedilol floating matrix tablets were evaluated for Angle of repose, 
Bulkdensity, Tapped density, Compressibility index and Hausner’s ratio.All the 
values were within the limit as per U.S.P. The best floatingperformance and the best 
in vitro drug release profile were achieved byformulation F4 which contains Drug: 
xanthan gum: karaya gum in aratio of 1:0.5:0.5 gave the drug release (99.64%) up to 
24 h. 
 
Ramnath Y.Lahareet al.,
31 
developed three new simple, economic 
spectrophotometric methods  for quantitative estimation of Rosuvastatin Calcium in 
bulk formulation. First method includes determination of Rosuvastatin Calcium at 
absorption maxima 252 nm, second method applied was area under curve for analysis 
of Rosuvastatin Calcium in the wavelength range of 247-257 nm and third method 
was first order derivative. Beer law obeyed in the concentration range of 5-35 μg/ml 
for all three methods. The correlation coefficients were found to be 0.974, 0.982 and 
0.982by absorption maxima, area under curve and first order derivative spectra. 
Results of analysis were validated statistically and by performing recovery studies. 
The mean percent recoveries were found satisfactory for all three methods. The 
percentage label claim was found in the range of 100.48% to 101.05%.  
 
Venkata srikanth meka et al.,
32
 enhanced the solubility of carvedilol phosphate and  
formulated it into non-effervescent floating tablets using swellable polymers. Solid 
dispersions (SD) of carvedilol were prepared with hydrophilic carriers such as 
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polyvinyl pyrrolidone and poloxamer to enhance solubility. Non-effervescent floating 
tablets were prepared with a combination of optimized solid dispersions and release 
retarding polymers/swellable polymers such as xanthan gum and polyethylene oxide. 
Tablets were evaluated for physicochemical properties such as hardness, thickness 
and buoyancy. SD prepared with the drug to poloxamer ratio of 1:4 by melt 
granulation showed a higher dissolution rate than all other dispersions. Formulations 
containing 40 mg of polyethylene oxide (C-P40) and 50 mg xanthan gum (C-X50) 
were found to be best, with the drug retardation up to 12 hours. Optimized 
formulations were characterized using FTIR and DSC and no drug and excipient 
interactions were detected. 
 
Nagesh C et al.,
33
 developed floating tablets of carvedilol using HPMC and various 
natural gums like guar gum and xanthan gum and gum ghatti along with incorporation 
of  gas generating agent, sodium bicarbonate.The floating tablet of carvedilol was 
prepared by wet granulation technique using solution of PVP K30 in isopropyl 
alcohol, using varying concentration of HPMC and natural gums.Post compressional 
parameters like hardness,thickness,friability,weightvariation,contentuniformity,in 
vitro buoyancy and in vitro dissolution studies were carried out. The results of  in 
vitro release of floating tablets containing natural gums has shown maximum drug 
release upto 97% in 24 hrs and remain buoyant for 24 hrs.  
 
BurraShashidheret al.,
34 
made an attempt to enhance the dissolution profile, 
absorption efficiency and bioavailability of water insoluble drugs, such as Carvedilol. 
A novel “Powder Solution Technology” involves absorption and adsorption 
efficiency, which makes use of liquid medications, admixed with suitable carriers, 
coating materials and formulated into a free flowing, dry looking, non adherent and 
compressible powder forms. Based upon a new mathematical model expression, 
improved flow characteristics and hardness of the formulation have been achieved by 
changing the proportion of Avicel ® PH 200 and Aerosil ® PH 200 from 20:1 ratio to 
5:1. Higher dissolution rates (90-99.9%) were observed in all liquisolid formulations, 
when compared with a conventional marketed product (CARCA®12.5 mg) within 
twenty minutes.  
 
Review of Literature 
 
Department of Pharmaceutics,Madras Medical College. Page 30 
 
Rohit B Mane et al.,
35
 prepared and evaluated of carvedilol microsphere using spray 
drying technique and to optimize the spray drying parameters to get the optimum 
formulation. The carvedilol microsphere were prepared by spray drying technique 
using ethyl cellulose and PEG 6000 as sustained release polymers. Nine batches were 
prepared by using ethyl cellulose and PEG 6000 in different polymer ratios and 
prepared microspheres were evaluated for the particle size, percentage drug 
entrapment and percentage drug release. Experimental designs were built to 
investigate the effects of five parameters on production yields and particle size of 
spray-dried microspheres of carvedilol. These factors concerned aspiration speed, 
flow rate, drug polymer ratio, temperature difference between inlet temperature and 
outlet temperature. Three formulations containing ethyl cellulose, PEG 6000 and 
carvedilol were tested. The aim of the study was to optimize the operating conditions 
to maximize production yields while minimizing the particle size. 
  
PisipatiAparnaet al.,
36
 developed and optimized carvedilol transdermal delivery 
system.Solvent casting method was used to prepare patches using polymethyl 
methacrylate (PMMA) and Eudragit E100 (EE100) polymers, dimethyl sulfoxide 
(DMSO) penetration enhancer, dibutyl phthalate (DBP) plasticizer and Tween 80 
surfactant. A 2
3
 factorial design was used based on three variables (PMMA, EE100, 
DMSO) at two levels Second order polynomial equations indicating interplay of 
ingredients were obtained by factorial design using SigmaTech software for 1, 4, 8 
and 20 h release data. so the design was extended to central composite design (CCD). 
The target formulation was obtained from contour plots and evaluated for various 
physicochemical parameters including in-vitro dissolution studies. 
 
BK Garget al.,
37
 developed and evaluated a pulsatile drug delivery system 
consisting of cores coated with two layers of swelling and rupturable coatings was 
prepared and evaluated as pulsatile drug delivery system. Cores containing 
Rosuvastatin calcium as model drug were prepared by direct compression of different 
ratios of spray-dried lactose and microcrystalline cellulose and were then coated 
sequentially with an inner swelling layer containing a super disintegrant 
(croscarmellose sodium) and an outer rupturable layer of ethylcellulose. The effect of 
level of swelling layer was investigated. Rupture and dissolution tests were performed 
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using the USP XXIV paddle method at 50 rpm in 0.1 N HCl. The lag time of the 
pulsatile release tablets decreased with increasing levels of swelling layer. Increasing 
levels of the ethylcellulose coating retarded the water uptake and thus prolonged the 
lag time. 
 
P. Rohini et al .,
38
 designed a formulation of orally disintegrating tablets of 
Rosuvastatin. Orally disintegrating tablets of Rosuvastatin were formulated by Super 
disintegrant addition method by direct compression technique. All the fourteen 
formulations were evaluated for disintegration time, hardness and friability, this Super 
disintegrant addition method exhibits the lowest disintegration time, hence it is ranked 
as the best among the methods. Further fourteen batches were prepared by using 
sodium starch glycolate, croscaramellose sodium, Lycoat Rs720 and cross povidone 
in different concentrations. All the formulations were evaluated for weight variation, 
hardness, friability, drug content, in-vitro disintegration time, wetting time, in-vitro 
dissolution study. Among all the formulations F13 (containing crosspovidone and 
sodium starch glycolate (1:1) (8%)) was considered to be the best formulation, which 
release up to 97% of the drug in 5 mins. A comparison of In vitro drug release was 
made with marketed product of Rosuvastatin which shows 93% drug release in 1 
hour. 
 
Dhiren S. Patel et al.
39
 developed  a versatile, accurate, precise and economic method 
for simultaneous determination of Rosuvastatin calcium and Aspirin in fixed dose 
combination products. The absorbance values at 242.0 nm and 297.0 nm and 287.5nm 
(isoabsorptive point) were used for the estimation of Rosuvastatin calcium and 
Aspirin, respectively without mutual interference. This method obeyed Beer’s law in 
the concentration range of 2–26 μg /ml for Rosuvastatin calcium and 5-25 μg /ml for 
Aspirin. The results of analysIs have been validated statistically for linearity, accuracy 
and precision, LOD and LOQ of the proposed method. 
 
Syed Zia Ul Quasimet al.,
40
 prepared a floating drug delivery system for the model 
drug Rosuvastatin calcium, and evaluating the various processing parameters 
including the buoyancy studies and in vitro drug release studies. Four formulations 
containing varying proportions of polymers like HPMC K4M and Ethyl cellulose and 
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fixed amount of gas generating agent such as Sodium bi carbonate and hydrophobic 
meltable material like bees wax were prepared. The tablets were prepared by melt 
granulation technique and the prepared tablets remained buoyant for more than 8hrs in 
the release medium. The proportions of the polymers showed significant difference in 
the release of the drug. All the formulations exhibited diffusion dominant drug release 
and were found to be stable. 
 
Chaudhari BG et al.,
41 
developed a simple and economical dual wavelength 
spectrophotometric method for the simultaneous estimation of rosuvastatin and 
diltiazem in their combined dosage forms. The method was based on property of 
addivity of absorbances. At 295.6 rosuvastatin showed absorbance but diltiazem 
showed zero absorbance. The two wavelengths on rosuvastatin curve were found out 
where it showed same absorbance, which were 227 and 247.4 nm. Diltiazem showed 
adequate absorbances at these wavelengths. The method involved solving of an 
equation based on measurement of absorbances at three wavelengths 295.6, 227, and 
247.4 nm. The proposed method was found to be simple, economical, accurate, and 
reproducible for routine analysis of both drugs in tablet dosage forms. 
 
BheemeswaraRao K et al.,
42
 developed the immediate release film coated 
formulation of Rosuvastatin Calcium to improve the distribution of Rosuvastatin 
calcium, improve the product stability.The immediate release formulation of 
Rosuvastatin Calcium was prepared by wet granulation method and by using fluidized 
bed coating method. Different formulations were made by using various 
concentrations of super disintegrant Poly plasdone XL-10 and granulating fluids like 
water, iso propyl alcohol (IPA) and Butyl hydoxytuolene (BHT). Opadry pink 
03k540019 was used as film coating mateial .The Prepared formulations were 
evaluated for the physical characteristics, invitro dissolution and stability at 40°C/ 
75% RH for three months. The formuation (F8) of film coated rosuvastatin calcium 
tablets showed best release profile. 
 
A. Ramuet al.,
43
 made a new attempt to enhance the solubility, dissolution rate 
and oral bioavailability of poorly soluble rosuvastatin by formulating it as solid 
dispersions using various techniques with polyethylene glycol (PEG) 6000 as a 
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carrier. Fast dissolving tablets of rosuvastatin were prepared with super disintegrants 
like sodium starch glycolate,croscarmellose sodium, pregelatinized starch and 
mannitol from the optimized solid dispersions. Tablets were evaluated for physical 
parameters and drug release by in vitro dissolution studies. Surface characteristics, 
drug-excipient interactions and crystal morphology of optimized solid dispersions 
were evaluated by SEM analysis, DSC and XRD studies, respectively. 
 
Ehsan ali Mohamed et al.,
44
 developed oro dispersible tablets of Rosuvastatin using 
different types of super disintegrants to enhance the disintegration and dissolution of 
Rosuvastatin to improve bioavailability of the drug.  Many trials were made to 
prepare a satisfactory rosuvastatin orodispersible tablet using direct compression and 
wet granulation method. Prepared tablets were evaluated for various parameters like 
weight variation, hardness, friability, wetting time, in vitro disintegration time, drug 
content, water absorption ratio and in vitro drug release. Formulas prepared by direct 
compression showed good flowability, while formulas prepared by wet granulation 
showed very poor flow properties. Various super disintegrants were used including 
croscarmellose (CCS), sodium starch glycolate (SSG) and crospovidone (CP), the 
latter found to be the best in term of showing the fastest disintegration time.  
 
GV.Wadageri et al.,
45
made an attempt to design and evaluate buccoadhesive bilayer 
tablets of carvedilol (beta blocker), in order to overcome bioavailability problems, to 
reduce dose dependent side effects and frequency of administration. Bilayer buccal 
tablets of carvedilol were prepared by direct compression method using combination 
of polymers (such as hydroxypropyl methylcellulose 15 cps, 50 cps and K4M along 
with Carbopol 934p and ethyl cellulose as backing layer. Fifteen formulations were 
developed with varying concentrations of polymers. The designed tablets were 
evaluated for various physical and biological parameters like drug content uniformity, 
in vitro drug release, short-term stability. Among the 15 formulations, the formulation 
F151 containing hydroxypropyl methylcellulose 15 cps (48% w/w of matrix layer), 
Carbopol 934p (2% w/w of matrix layer) and mannitol (channeling agent, 34.5% w/w 
of matrix layer) was found to be promising. 
Y.Nirupa rani et al.,
46 
developed and validated simple, sensitive and specific 
spectrophotometric method for the determination of Carvedilol, an alpha adrenergic 
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receptor blocker, anti hypertensive drug in pure form and in pharmaceutical 
formulations by UV visible spectroscopic methods. The developed method was 
validated with respect to linearity, accuracy, precision and specificity. The adequate 
drug solubility and maximum sensitivity was found in chloroform. The λmax or the 
absorption maxima of the drug was found to be 286 nm. The calibration range was 
studied from 50% ‐150% and correlation was found to be R2 = 0.998 which was 
within the limits of ICH guidelines. They analyzed and evaluated an analytical 
method and compared with validation report generated for the developed method. No 
interference was found from excipients at the selected wavelength and analysis 
conditions. 
 
Anandakumar Karunakaranet al.,
47 
described two methods for the simultaneous 
estimation of  Rosuvastatin Calcium and Fenofibrate in binary mixture. The first 
method was based on UV Spectrophotometric determination of two drugs, using 
simultaneous equation method. It involves absorbance measurement at 243nm (λmax 
of Rosuvastatin Calcium) and 287nm (λmax of Fenofibrate) in methanol; linearity 
was obtained in the range of 1-6 µg/ml and 4-28 µg/ml for Rosuvastatin Calcium and 
Fenofibrate, respectively. The second method was based on HPLC separation of two 
drugs in reverse phase mode using Luna C18 column. Linearity was obtained in the 
concentration of 1-7 µg/ml and 4-28 µg/ml for Rosuvastatin Calcium and Fenofibrate, 
respectively. Both these methods have been successively applied to pharmaceutical 
formulation and were validated according to ICH guidelines. 
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AIM OF THE WORK 
 To combine Rosuvastatin calcium and Carvedilol in a single dosage form  due to their 
cardioprotective effects on various cardiovascular events. 
 To increase the gastric residence time of formulation in order to increase the 
bioavailability and efficacy of drug for better patient compliance by giving in floating 
drug delivery system. 
 To optimize the immediate release tablet of Rosuvastatin Calcium by direct 
compression method using various super disintegrants such as Sodium Starch 
Glycolate, Crospovidone and Croscarmellose Sodium. 
 To optimize the gastroretentive floating layer tablets of Carvedilol by Direct 
             compression method using natural and synthetic polymer such as Xanthan gum, guar 
 gum and  HPMC K 100 in different ratios. 
 To formulate and evaluate the gastroretentive bilayer floating tablets from the 
             optimized batches of immediate and floating tablet formulations. 
PLAN OF WORK 
 Preformulation studies. 
 Raw material analysis 
 Physical and chemical compatibility studies 
 Construction of Calibration curve. 
 Precompression studies of drug and blends. 
 Bulk density 
 Tapped density 
 Angle of repose 
 Carr’s index 
 Hausner’s ratio 
 Formulation of immediate release (IR) compressed tablets. 
 Post compression studies of IR tablets for physical parameters like 
 Physical appearance 
 Uniformity of weight 
 Hardness, thickness, diameter 
 Friability  
 Determination of drug content of tablets 
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 Disintegration studies of IR tablets. 
 In-vitro dissolution studies of IR tablets. 
 Formulation of Floating tablets. 
 Post compression studies of Floating tablets for physical parameters like 
 Physical appearance 
 Hardness, Thickness, Diameter and Friability 
 Determination of drug content of floating tablets 
 Uniformity of weight 
 Evaluation of floating characteristics of floating tablets- Buoyancy test. 
 In-vitro dissolution studies of floating tablets. 
 Formulation of Bilayer Floating Tablets (BFT). 
 Post compression studies of bilayer floating tablets like 
 Uniformity of weight 
 Hardness, thickness, diameter and friability 
 Determination of drug content 
 Evaluation of floating characteristics of bilayer floating tablets 
 In-vitro dissolution studies of bilayer Floating tablets. 
 Evaluation of release kinetics of BFT. 
 Stability studies of prepared tablets as per ICH guidelines 
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RATIONALE FOR COMBINING ROSUVASTATIN CALCIUM AND 
CARVEDILOL IN GASTRO RETENTIVE DRUG DELIVERY:
48,49,50
 
 Cardiovascular diseases are one of the life threatening diseases of the world. It 
mainly includes arteriosclerosis, coronary artery disease i.e. angina pectoris, 
myocardial infarction, congestive cardiac failure, cardiac arrhythmias, angina 
pectoris, hypertension, hyperlipidemia etc.  
 Hypertension and dyslipidemia are conditions that can coexist frequently. 
National Health and Nutrition Examination Survey (NHANES III) has shown that 
64% of patients with hypertension also have dyslipidemia and conversely, 
approximately 47% of patients with dyslipidemia have hypertension. 
 Rosuvastatin Calcium and Carvedilol are often prescribed simultaneously in 
cardiac prescriptions. More  of cardiac events can be prevented when these 
drugs are given in combination. So it could be an appropriate cardio protective 
formulation with the treatment of Hyperlipidemia and Hypertension.  
 And the gastroretentive drug delivery system is one in which the 
gastroretentive dosage form releases the drug over an extended period in the 
stomach and upper GIT thus, enhancing the opportunity of absorption. Both 
the drugs have narrow absorption window in the upper GIT and they  are 
suitable for gastro retentive drug delivery.    
 
RATIONALE FOR SELECTION OF ROSUVASTATIN CALCIUM OVER 
OTHER STATINS
50
: 
 Rosuvastatin Calcium is a currently used anti-hyperlipidemicagent.It is a first 
line drug for coronary artery disease. 
 It is a selective and competitive inhibitor ofHMG-CoA reductase. 
 It is the most effective statin at reducing LDL-C,triglycerides and total 
cholesterol. 
 It reduces 40 – 70 %  LDL level. 
 The half life of Rosuvastatin Calcium is 19 hrs.  So it is suitable for immediate 
release formulation. 
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RATIONALE FOR SELECTION OF CARVEDILOL OVER TRADITIONAL 
BETA BLOCKERS
51
 
 Carvedilol is a nonselectiveβ-adrenergic blocking agent with α1-blocking 
activity prescribed for the treatment of angina, hypertension and congestive 
heart failure. 
 Traditional beta blockers have been shown to facilitate weight gain and 
increase triglycerides.  
 Carvedilol has been found to have a neutral effect on weight and triglycerides. 
So it is the better choice compared to traditional beta blockers in the high risk 
cardiac patients with hyperlipidemia. 
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DYSLIPIDEMIA
52,53
 
DEFINITION: 
Dyslipidemia is an abnormal amount of lipids (cholesterol and / or fat) in the 
blood. In developed countries, most dyslipidemias are hyperlipidemias; that is an 
elevation of lipids in the blood. This is often due to diet and lifestyle. Prolonged 
elevation of insulin levels canal so lead to dyslipidemia. Likewise, increased levels of 
O-Glc NA transferase (OGT) may cause dyslipidemia. 
HYPERLIPIDEMIA 
The lipids of human plasma are transported in macromolecular complexes 
termed lipoproteins. A number of metabolic disorders that involve elevations in levels 
of any of the lipoprotein species are thus termed hyper lipoproteinemias or 
hyperlipidemias. Term hyperlipidemia denotes increased levels of triglycerides in 
plasma. Hyperlipidemia is a major cause of atherosclerosis and atherosclerosis- 
associated conditions such as coronary heart disease (CHD), ischemic cerebro 
vascular disease and peripheral vascular disease. 
Hyperlipidemia (elevated levels of triglycerides or cholesterol) and a reduced 
HDL-C level occurs as a consequence of several interrelated factors that affect the 
concentrations of the various plasma lipoproteins. These factors may be lifestyle or 
behavioural (diet or exercise), genetic (mutations in gene regulating lipoprotein 
levels) or metabolic (diabetes mellitus) or other conditions that influence plasma 
lipoprotein metabolism. 
Lipoprotein transport in the blood 
Lipids and cholesterol are transported through the blood as macromolecular 
complexes of lipid and protein known as lipoproteins. These consist of a central core 
of hydrophobic lipid (triglycerides and cholestryl esters) encased in a more 
hydrophilic coat of polar substances- phospholipids, free cholesterol and associated 
apolipoproteins. There are four main classes of lipoproteins differing in relative 
proportion of the core lipids and in the type of apoprotein. They differ on the basis of 
their size and density. 
They are classified into: 
1. High density lipoproteins (HDL) 
2. Low density lipoproteins (LDL) 
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3. Very Low density lipoproteins (VLDL) 
4. Chylomicrons 
Each of this lipoprotein classes has a specific role in lipid transport in the 
circulation and there are different pathways for exogenous and endogenous lipids. In 
the exogenous pathway cholesterol and triglycerides are absorbed from the 
gastrointestinal tract and transported in the lymph and then in the plasma as 
chylomicrons (diameter 100-1000 nm) to muscle and adipose tissue. Here the cores of 
chylomicrons are hydrolyzed by lipoprotein lipase and the tissues take up the resulting 
free fatty acids. The chylomicron remnants (30-50receptors on hepatocytes and 
undergo endocytosis. Cholesterol is liberated within the liver cell and may be stored, 
oxidized to bile acids or secreted in the bile unaltered. Alternatively, it may enter the 
endogenous pathway of lipid transport in VLDL. In the endogenous pathway 
cholesterol and newly synthesized triglycerides are transported from the liver as 
VLDL (30-80nm) to muscle and adipose tissues where the triglycerides are 
hydrolyzed and the resulting fatty acids enter the tissues. During this process the 
lipoprotein particles become smaller (20-30nm) but still have a full complement of 
cholesteryl esters and ultimately become LDL, which provides the source of 
cholesterol for incorporation into cell membranes and for synthesis of steroids and 
bile acid. 
ETIOLOGY: 
Primary and secondary causes contribute to dyslipidemia. 
PRIMARY CAUSES 
Primary causes are single and multiple gene mutations that result in either 
overproduction or defective clearance of TG and LDL cholesterol or in under 
production or excessive clearance of HDL. 
SECONDARY CAUSES: 
Secondary causes contribute to most cases of dyslipidemia in adults. The most 
important secondary cause in developed countries is a sedentary lifestyle with 
excessive dietary intake of saturated fat, cholesterol and transfats. Diabetes is an 
especially significant secondary cause because patients tend to have anatherogenic 
combination of high TGs; high small, dense LDL fractions; and low HDL(diabetic 
dyslipidemia). Patients with type 2 diabetes are especially at risk. 
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SIGNS AND SYMPTOMS: 
 Dyslipidemia itself usually causes no symptoms but can lead to symptomatic 
vascular diseases including coronary artery disease (CAD) and peripheral 
arterial disease. 
 High levels of TGs (>1000mg/dL) can cause acute pancreatitis. 
 High levels of LDL can cause eyelid xanthelasmas; arcuscorneae; and 
tendinous xanthomas at the Achilles, elbow and knee tendons and over meta 
carpophalangeal joints. 
 Severe hyper tri glyceridemia (>2000mg/dL) can give retinal arteries a 
creamy white appearance (lipemiaretinalis). 
 Extremely high lipid levels give a lactescent (milky) appearance to plasma. 
 Symptoms include Parasthesias, Dyspnea and Confusion. 
SCREENING: 
A Fasting lipid profile (TC, TG, HDL-C, LDL-C) should be obtained in all 
adults ≥20 years and should be repeated every five years. 
MANAGEMENT: 
The main goal of dyslipidemia management is to maintain blood cholesterol 
level within the normal range as possible. 
 Lifestyle modification focusing on the reduction of saturated fat and 
cholesterol intake. 
 Weight loss. 
 Increased physical activity. 
 Smoking cessation 
TREATMENT: 
DRUGS- FOUR CLASSES OF LIPID LOWERING DRUGS ARE 
 HMG-CoA reductase inhibitors (Statins): 
           Lovastatin, simvastatin, pravastatin, atorvastin, rosuvastin. 
 Bile acid sequestrants (Resins):Cholestyramine, colestipol. 
 Activate lipoprotein lipase (Fibric acid derivatives): 
Clofibrate, gemfibrozil, benzafibrate, and fenofibrate. 
 Inhibit lipolysis and triglyceride synthesis: Nicotinic acid 
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HYPERTENSION
54,55,56
 
Blood is carried from the heart to all parts of the body in blood vessels. Each 
time the heart beats, it pumps blood into the vessels. Blood pressure is created by the 
force of blood pushing against the walls of blood vessels (arteries) as it is pumped by 
the heart. Hypertension, also known as high or raised blood pressure, is a condition in 
which the blood vessels have persistently raised pressure. The higher the pressure in 
blood vessels the harder the heart has to work in order to pump blood. If left 
uncontrolled, hyper tension can lead to a heart attack, an enlargement of the heart and 
eventually heart failure. Hypertension can also lead to kidney failure, blindness, 
rupture of blood vessels and cognitive impairment. 
Blood pressure is measured in millimeters of mercury (mm Hg) and is 
recorded as two numbers usually written one above the other. The upper number is 
the systolic blood pressure the highest pressure in blood vessels and happens when the 
heart contracts, or beats. The lower number is the diastolic blood pressure- the lowest 
pressure in blood vessels in between heart beats when the heart muscle relaxes. 
Normal adult blood pressure is defined as a systolic blood pressure of 120 mmHg and 
a diastolic blood pressure of 80 mmHg. 
Table 1: Classification of hypertension 
Category Systolic BP (mmHg) Diastolic BP (mmHg) 
Optimal <120 <80 
Normal 120–129 80–84 
High normal 130–139 85–89 
Grade 1 hypertension 140–159 90–99 
Grade 2 hypertension 160–179 100–109 
Grade 3 hypertension ≥180 ≥110 
 
Etiology: 
Hypertension is either due to some cause or without identifiable cause. There 
are two types of hypertension. 
1. Primary hypertension 
2. Secondary hypertension 
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Primary hypertension:  
Primary (essential) hypertension is the most common form of hypertension, 
accounting for 90–95% of all cases of hypertension. In almost all contemporary 
societies, blood pressure rises with aging and the risk of becoming hypertensive in 
later life is considerable. Hypertension results from a complex interaction of genes 
and environmental factors. 
Genetic factors: 
 The role of heredity in the etiology of essential hypertension has long 
suspected; e.g. occurrences of hypertension in twins. 
Racial and environmental factors:  
During a survey in US, it was revealed that the incidence of hypertension in 
black is more than whites. Environmental factors like salt intake, obesity has 
influence on the hypertension. 
Pathophysiology: 
 Hypertension is a risk factor for atherosclerosis and cardiovascular 
complications like myocardial infarction, angina pectoris, and congestive cardiac 
failure, whether the cause of hypertension is known or unknown. In secondary 
hypertension, in less than 10% cases causes of hypertension are understood whereas 
in more than 90% cases, the mechanism of essential hypertension remains largely 
obscure. In general, two hemodynamic forces viz-cardiac output and peripheral 
resistance regulate the normal blood pressure. The role of kidney particularly in 
secondary hypertension by elaboration of rennin and subsequent formation of 
angiotensin II is well established. Chronic hypertension results in damage to end 
organs like eyes, brain, kidneys and heart. It is possible to correlate the duration of 
hypertension by considering the severity of end organ damage. 
Secondary Hypertension: 
It is secondary to some other underlying disease. When the actual cause is 
treated hypertension comes to normal. 
Underlying causes may be as follow: 
1. Rennin angiotensin mediated hypertension. 
2. Endocrine disorders 
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There are following types of hypertension: 
Renal hypertension: 
Renal diseases like renal vascular hypertension produce renal hypertension, 
which is associated with the renal artery. Renal hypertension may be produced by any 
one of three interrelated mechanisms 
a) Activation of renin-angiotensin system. 
b) Sodium and water retention. 
c) Decreased release of vasodepressor materials. 
Endocrine hypertension: 
 A number of hormonal secretions may produce secondary 
hypertension like adrenal glands, parathyroid glands, and oral contraceptives. Usually, 
hypersecretion of tumour of endocrine glands; e.g. Cushing’s syndrome, primary 
hyper aldosteronism, pheochromocytoma, oral contraceptives, and use may lead to 
release of angiotensin I. 
Neurogenic:  
Psychogenic polyneuritis, increased intracranial hypertension and secretion of 
spinal cord are the uncommon causes of secondary hypertension. 
Contraction of aorta: 
Causes secondary hypertension in the upper part of the body due to 
constriction. Diastolic hypertension results from changes in circulation. 
Causes of hypertension 
Behavioral risk factors: 
There are many behavioral risk factors for the development of hypertension 
including: 
 Consumption of food containing too much salt and fat, and not 
eating enough fruit and vegetables 
 Harmful levels of alcohol use 
 Physical inactivity and lack of exercise 
 Poor stress management. 
Socioeconomic factors:  
Social determinants of health, e.g. income, education and housing, have 
an adverse impact on behavioral risk factors and in this way influence the 
development of hypertension. 
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Other factors: 
In some cases there is no known specific cause for hypertension. Genetic 
factors may play a role, and when hypertension develops in people below the age of 
40 years, it is important to exclude a secondary cause such as kidney disease, 
endocrine disease and malformations of blood vessels. Preeclampsia is hypertension 
that occurs in some women during pregnancy. It usually resolves after the birth but it 
can sometimes linger, and women who experience preeclampsia are more likely to 
have hypertension in later life. 
Symptoms of high blood pressure 
  There is a common misconception that people with hypertension always 
experience symptoms, but the reality is that most hypertensive people have no 
symptoms at all. Sometimes hypertension causes symptoms such as, 
 headache, 
 shortness of breath,  
 dizziness,  
 chest pain, 
 palpitations of the heart and  
 nose bleeds.  
 It can be dangerous to ignore such symptoms, but neither can they be relied 
upon to signify hypertension. Hypertension is a serious warning sign that significant 
lifestyle changes are required. The condition can be a silent killer and it is important 
for everybody to know their blood pressure reading. 
Treatment  
 Diuretics 
 Angiotensin converting enzymes (ACE) inhibitors 
 Alpha adrenergic receptor blockers 
 Beta adrenergic receptor blockers 
 Calcium channel blockers 
 Central adrenergic inhibitors 
 Vasodilators 
 Lifestyle modification to reduce risk factors 
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ROSUVASTATIN CALCIUM
58,59,60
 
Rosuvastatin calcium is a synthetic lipid lowering agent which is an inhibitor of 3-
hydroxy-3-Methylglutaryl-coenzyme A (HMG-Co-A) reductase. This enzyme catalyzes 
the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol 
biosynthesis. 
Chemical structure: 
                              
 
Chemical Name:   Bis[(E)-7-[4-(flurophenyl)-6-isopropyl-2- [methyl 
(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3-5-dihydroxyhept-6-
enoic acid] calcium salt 
Molecular formula:(C22H27FN3O6S)2Ca 
Molecular weight:1001.14 
Melting point: 151-156ºC 
Dosage and administration:5 to 40 mg per day orally 
Description    : An off white to creamish white crystalline powder 
Solubility  : Soluble in methanol and Dimethyl sulphoxide, practically insoluble in      
water. 
Mechanism of Action: 
 Rosuvastatin is a selective and competitive inhibitor of HMG-Co-A reductase, the 
rate-limiting enzyme that converts -3-hydroxy-3- methyl glutaryl coenzyme A to 
mevalonate, a precursor of cholesterol. 
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Table 2.Effect of drugs on LDL and HDL levels 
          Treatment      LDL- C reduction       HDL- C increase 
    Atorvastatin (10-80 mg)                  37-51 %                5.7-2 % 
    Simvastatin (10-80 mg)                  28-46 %                5.3 -6.8 % 
Rosuvastatin (10-40 mg)                  46-55 %                7.6-9.6 % 
    Pravastatin (10-40 mg)                  20-30 %                3.2-5.5 % 
 
Pharmacokinetics 
Absorption:  
Absolute bioavailability is 20 %. The half-life is 19 hrs and does not increase with 
increasing dose. Significant LDL-C reductions are seen when rosuvastatin is given with or 
without food, and not considering time of day of drug administration. 
Distribution: 
Volume of distribution of rosuvastatin at steady state is approximately 134 litres. 
Rosuvastatin is approximately 90% bound to plasma proteins, mostly albumin. 
Metabolism:  
Rosuvastatin is not extensively metabolised; about 10% of a radio labelled dose is 
recovered as metabolite. 
Excretion: 
Rosuvastatin undergoes limited metabolism (approximately 10%), mainly to the   
N- desmethylform, and 90% is eliminated as unchanged drug in the faeces with the 
remainder being excreted in the urine. The elimination half-life (t1/2) of rosuvastatin is 
approximately 19 hrs. 
Drug-Drug Interactions 
Ketoconazole, Erythromycin, Cyclosporine, Warfarin, Digoxin and Oral 
contraceptives. 
Adverse effects   
Rosuvastatin calcium is generally well tolerated. The adverse events seen with 
rosuvastatin are generally mild and transient. 
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Central Nervous System:  
Dizziness 
Gastrointestinal: 
Constipation, nausea, abdominal pain and pancreatitis (rare) 
Musculoskeletal: 
 Myalgia, asthenia, myopathy (including myositis) and rhabdomyolysis (rare) 
Skin:  
Pruritus, rash, urticaria, hypersensitivity reactions including angioedema (rare) 
Miscellaneous:  
Headache 
Indications and clinical uses 
Rosuvastatin calcium is indicated as an adjunct to diet, at least equivalent to the 
Adult Treatment .Panel III (ATP III TLC diet), for the reduction of elevated total 
cholesterol, LDL-cholesterol, the total cholesterol: HDL-cholesterol ratio and triglycerides 
and for increasing HDL-C;in hyperlipidemic and dyslipidemic conditions, when response 
to diet and exercise alone has 
been inadequate including: 
o Primary hypercholesterolemia (Type IIa including heterozygous familial 
hypercholesterolemia and severe non-familial hypercholesterolemia) 
o Combined (mixed) dyslipidemia (Type IIb) 
o Homozygous familial hypercholesterolemia where rosuvastatin calcium is 
used either alone or as an adjunct to diet and other lipid lowering treatment 
such as aphaeresis. 
Contraindications 
o Rosuvastatin calcium is contraindicated in patients with a known 
hypersensitivity to any component of this product.  
o Rosuvastatin is contraindicated in patients with active liver disease orwith 
unexplained persistent elevations of serum transaminases. 
o HMG-Co-A reductase inhibitors are contraindicated during pregnancy and 
in nursing mothers. 
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CARVEDILOL
61,62,63,64
: 
Carvedilol is a nonselective β-adrenergic blocking agent with additional α1-blocking 
activity. 
Chemical structure : 
                              
Chemical name : 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy) ethyl]                              
amino]- 2-propanol  
Molecular weight  : 406.47  
Molecular formula  : C24H26N2O2 
Category                : Non selective β –adrenergic blocker with α1 – blocking 
activity 
Dosage & administration: 3.125, 6.25, 12.5 to 25 mg per day orally.  
Description : A white or almost white crystalline powder; Colorless crystals 
from ethyl acetate . 
Solubility : Freely soluble in DMSO; soluble in methylene chloride 
(CH2Cl2); Methanol; sparingly soluble in ethanol, 
isopropanol; slightly soluble in ethyl ether; practically 
insoluble in water & dilute acids . 
Melting point  : 114 – 1150C  
Mechanism of action: 
 Carvedilol is  a racemic mixture in which nonselective β-adrenoreceptor blocking 
activity is present in the S(-) enantiomer and α1-adrenergic blocking activity is 
present in both R(+) and S(-) enantiomers at equal potency. 
 Carvedilol has no intrinsic sympathomimetic activity.Carvedilol beta adrenergic 
receptor blocking ability decreases the heart rate, myocardial contractility and 
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myocardial oxygen demand. Carvedilol also decreases systemic vascular resistance 
via its alpha adrenergic receptor blocking properties. 
Absorption: 
Carvedilol is rapidly and extensively absorbed following oral administration, with 
an absolute bioavailability of approximately 25% to 35% due to a significant degree of 
first-pass metabolism. Plasma concentrations achieved are proportional to the oral dose 
administered. When administered with food, the rate of absorption is slowed, as evidenced 
by a delay in the time to reach peak plasma levels, with no significant difference in extent 
of bioavailability.  
Half-life (t1/2): 
7 to 10 hrs 
Volume of Distribution (Vd):  
115 L 
Protein binding:   
98 %, primarily with albumin. The plasma-protein binding is independent of 
concentration over the therapeutic range. 
Metabolism: 
Carvedilol is metabolized primarily by aromatic ring oxidation and 
glucuronidation. The oxidative metabolites are further metabolized by conjugation via 
glucuronidation and sulfation. The metabolites of carvedilol are excreted primarily via the 
bile into the feces. Demethylation and hydroxylation at the phenol ring produce 3 active 
metabolites with β-receptor blocking activity. the 4'-hydroxyphenyl metabolite is 
approximately 13 times more potent than carvedilol for β-blockade. 
Elimination: 
   Less than 2% of the dose was excreted unchanged in the urine. The metabolites of 
carvedilol are excreted primarily via the bile into the feces.  
Clearance: 500 to700 mL/min. 
Therapeutic indication : 
In the treatment of 
             Hypertension,  
Congestive heart failure, 
  Angina pectoris. 
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Drug interactions: 
Digoxin,Insulin or oral hypoglycemics,Inducers and inhibitors of hepatic 
metabolism. 
Contraindications 
Hypersensitivity to carvedilol or any component of the product, 
Pregnancy and lactation, 
Cardiogenic shock, 
History of bronchospasm or asthma. 
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3. EXCIPIENT PROFILE 
PHARMACEUTICAL EXCIPIENTS: 
 Excipients are substances other than the pharmacologically active drug or 
prodrugs, which are included in the manufacturing process or contained in the 
pharmaceutical finished product or dosage form. 
 Excipients play a wide variety of functional role in pharmaceuticals dosage 
forms including, 
 Modifies the solubility and bioavailability of active pharmaceutical 
ingredients (APIs). 
 Increasing the stability of active ingredients the dosage forms. 
 Maintaining the pH and/or osmolarity of liquid formulations. 
 Helping active ingredients maintained preferred polymorphic 
Forms or conformation. 
 Modulating immunogenic responses of active ingredients 
(e.g.adjuvants). 
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HYDROXY PROPYL METHYL CELLULOSE
65
 
1. Non-proprietary Name: 
 BP: Hypromellose, JP: Hypromellose PhEur: Hypromellose  
USP: Hypromellose 
2. Synonyms: 
Benecel MHPC, E464, hydroxyl propyl methyl cellulose, HPMC 
hypromellosum, methocel, methyl cellulose propylene glycol ether, methyl 
hydroxylpropyl cellulose, metolose , MHPC,Pharmacoat, Tylophor, Tylose. 
3. Chemical Name: Cellulose hydroxyl propyl methyl ether. 
4. Molecular weight: Molecular weight approximately 10000-1500000. 
5. Functional category: 
Bio adhesive material, coating agent, controlled release agent, 
emulsifying agent,film forming agent, suspending agent, sustained release 
agent and tablet binder etc., 
6. Description: 
Hypromellose is an odourless and tasteless, white or creamy – white  
fibrous or granular powder. 
7. Solubility : 
Soluble in cold water, forming a viscous colloidal solution; practically 
insoluble in hot water, chloroform, ethanol (95%) and ether. 
8. Applications: 
HPMC is widely used in oral, ophthalmic, nasal and topical 
pharmaceutical formulations. It is used as tablet binder in film-coating and as a 
matrix for extended release tablet formulations, concentrations between 2-5% 
used as binder in either wet or dry granulation processes. High viscosity grades 
may be used to retard the release of drugs from a matrix at levels of 10-
80%w/w in tablets and capsules. Hypromellose is also used in liquid oral 
dosage forms as a suspending and/or thickening agent at concentrations 
ranging from 0.25-5.0%. 
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XANTHAN GUM
65
 
1. Non-proprietary names: 
 BP, USP-NF: Xanthan gum, PhEur: Xanthani gummi 
2. Synonyms: 
Corn sugar gum, E415, Keltrol,poly saccharide B-1459, Rhodigel, Vansan NF, 
Xantural. 
3. Chemical name: Xanthan gum 
4. Empirical formula and Molecular weight: 
 (C35H49O29)n. Xanthan gum as a high molecular weight polysaccharide gum. 
Itcontains D-glucose and D-mannose as a dominant hexose units, along with D- 
glucuronic acid and is prepared as the sodium, potassium or calcium salt. 
5. Structural formula: 
Each xanthan gum repeat units contains five sugar residues: two glucose, two 
mannose and one glucuronic acid. The polymer backbone consist of four b-D-glucose 
units linked the 1 and 4 positions and is therefore identical in structure to cellulose 
6. Functional category: 
Stabilizing agent; viscosity increasing agent; suspending agent. 
7. Description: 
Xanthan gum occurs as a cream or white colored odourless, free flowing, fine 
powder. 
8. Applications: 
 Xanthan gum is widely used in oral and topical formulation cosmetics and 
food as a stabilizing agent. It is also used as emulsifying agent and thickening agent, it 
is nontoxic,compatible with most other pharmaceutical ingredients and has good 
stability and viscosity properties over wide pH and temperature range, it is also used 
as a matrix former in sustained release tablets, it increases the retention time of the 
ophthalmic solutions in eye and as bioadhesive polymer. 
 
Excipient Profile 
 
Department of Pharmaceutics, Madras Medical College Page 55 
 
 
GUAR GUM
65
 
1. Nonproprietary Names 
 BP     :Guar galactomannan 
            Ph.Eur   :Guar galactomanan 
 USP –NF: Guar gum 
2. Synonyms 
 Galactosol,Guar flour, Jaguar gum, Meyprogat, Meyprodor, Meyprofin 
3. Chemical Name and CAS Number 
 Galactomannan polysaccharide & [9000-30-0] 
4. Empirical Formula and Molecular Weight 
  (C6H12O6)n and 220.000 
5. Description 
 Guar gum occurs as an odourless or nearly odourless, white to yellowish-white 
powder with a bland taste. 
6. Solubility 
Practically insoluble in organic solvents, cold or hot water, Guar gum 
disperses and swells almost immediately to form a highly viscous, thixotropic sol. The 
optimum rate of hydration occurs at pH 7.5 – 9.0. 
7. Functional Category 
Suspending agent, tablet binder, tablet disintegrant, viscosity increasing agent 
8. Applications in Pharmaceutical Formulation or Technology 
Guar gum is used in cosmetics, food products, and pharmaceutical 
formulations. It has also been investigated in the preparation of sustained release 
matrix tablets in the place of cellulose derivatives such as methylcellulose. In 
pharmaceuticals, guar gum is used in solid-dosage forms as a binder and disintegrant; 
in oral and topical products as a suspending, thickening and stabilizing agent; and also 
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as a controlled-release carrier. Guar gum has also been examined for use in colonic 
drug delivery & oral controlled release formulations. 
9. Stability and Storage Conditions 
Aqueous guar gum dispersions have a buffering action and are stable at pH 
4.0-10.5. However, prolonged action reduces the viscosity of dispersions. The 
bacteriological stability of guar gum dispersions may be improved by the addition of a 
mixture of 0.15%methylparaben and 0.02% propyl paraben as a preservative. In food 
applications, benzoic acid, citric acid, sodium benzoate or sorbic acid may be used. 
Guar gum powder should be stored in a well-closed container in a cool and dry place. 
10. Incompatibilities 
  Guar gum is compatible with most other plant hydrocolloids such as 
tragacanth. Itis incompatible with acetone, ethanol (95%), tannins, strong acids and 
alkalis. Borate ions, if present in the dispersing water, will prevent the hydration of 
guar gum. However the addition of borate ions to hydrated guar gum produces 
cohesive structured gels and further hydration is then prevented. The gel formed can 
be liquefied by reducing the pH to below 7 or by heating. Guar gum may reduce the 
absorption of Penicillin V from some formulations by a quarter. 
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SODIUM STARCH GLYCOLATE
65 
1. Non-proprietary name 
  BP: Sodium starch glycolate, Ph.Eur: sodium starch glycolate. 
2. Synonyms 
Carboxymethyl starch, sodium salt, carboxy methyl amylum natricum; 
Explosol, glycolys, primojel, tablo, viva star p. 
3. Chemical name: 
Sodium carboxy methyl starch. 
4. Functional category: 
Tablet and capsule disintegrant. 
5. Description: 
Sodium starch glycolate is a white or almost white free- flowing hygroscopic 
powder. 
6. Solubility: 
Practically insoluble in methylene chloride; It gives a translucent suspension in 
water. 
7. Applications: 
It is widely used in oral pharmaceuticals as a disintegrant in capsule and tablet 
formulations. It is commonly used in tablet prepared by direct compression or wet 
granulation process. The usual concentration employed in formulation is between 2% 
and 8%, with the optimum concentration of about 4%.disintegration occurs by rapid 
uptake of water and enormous swelling. Increasing the tablet compression pressure 
also appears to have no effect on disintegration time.  
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CROSPOVIDONE
65 
1. Non-proprietary Name: 
BP: Crospovidone PhEur: Crospovidonum USP-NF: Crospovidone 
2. Synonyms: 
Crosslinkedpovidone, E1202;Kollidon CL, Kollidon CL-M, Polyplasdone 
XL,Polyplasdone XL-10; polyvinylpolypyrrolidone,PVPP,1-vinyl-2-pyrrolidinone 
homopolymer. 
3. Chemical Name: 
1-Ethenyl-2-pyrrolidinone homopolymer. 
4. Molecular weight:Molecular weight approximately >1 000 000 
5. Functional category:  Tablet disintegrant. 
6. Description: 
Crospovidone is a white to creamy-white, finely divided, freeflowing, 
practically tasteless, odourless or nearly odourless, hygroscopic powder. 
7. Solubility: 
Soluble in cold water, forming a viscous colloidal solution; practically 
insoluble in hot water, chloroform, ethanol (95%) and ether. 
8. Applications: 
Crospovidone is a water-insoluble tablet disintegrant and dissolution agent 
used at 2–5% concentration in tablets prepared by direct-compression or wet- and dry 
granulation methods. It rapidly exhibits high capillary activity and pronounced 
hydration capacity, with little tendency to form gels. Studies suggest that the particle 
size of crospovidone strongly influences disintegration of analgesic tablets. Larger 
particles provide a faster disintegration than smaller particles. Crospovidone can also 
be used as a solubility enhancer. With the technique of co-evaporation, crospovidone 
can be used to enhance the solubility of poorly soluble drugs. The drug is adsorbed on 
to crospovidone in the presence of a suitable solvent and the solvent is then 
evaporated. This technique results in faster dissolution rate. 
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CROSCARMELLOSE SODIUM
65
 
1. Non-proprietary Name: 
BP: Croscarmellose sodium, PhEur: Croscarmellose natriumconexum USP: 
Croscarmellose sodium 
2. Synonyms: 
Ac-Di-Sol; cross linked carboxy methylcellulose sodium; Explocel; modified 
cellulose gum; Nymcel ZSX; Pharmacel XL; Primellose; Solutab; Vivasol. 
3. Chemical Name:Cellulose, carboxy methyl ether, sodium salt. 
4. Molecular weight:Molecular weight approximately 90000-700000 
5. Functional category:Tablet and capsule disintegrant 
6. Description: 
Croscarmellose sodium occurs as an odourless, white or grayish white powder 
7. Applications: 
Croscarmellose sodium is used in oral pharmaceutical formulations as a 
disintegrant for capsules, tablets and granules. In tablet formulations, croscarmellose 
sodium may be used in both direct-compression and wet-granulation processes. When 
used in wet granulations, the croscarmellose sodium should be added in both the wet 
and dry stages of the process (intra- and extra granularly) so that the wicking and 
swelling ability of the disintegrant is best utilized. Croscarmellose sodium at 
concentrations up to5% w/w may be used as a tablet disintegrant, although normally 
2% w/w is used in tablets prepared by direct compression and 3% w/w in tablets 
prepared by a wet granulation process. 
8. Incompatibilities 
The efficacy of disintegrants, such as croscarmellose sodium, may be slightly reduced 
in tablet formulations prepared by either the wet-granulation or direct compression 
process that contain hygroscopic excipients such as sorbitol. Croscarmellose sodium is 
not compatible with strong acids or with soluble salts of iron and some other metals 
such as aluminum, mercury, and zinc. 
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POVIDONE
65
 
1. Nonproprietary name 
Povidone 
2. Synonyms: 
E1201, kollidon, plasdone, poly[1-(2-oxo-1-pyrolidinyl) ethylene] 
polyvidone;polyvinyl pyrrolidone, povidone, PVP; povipharm 1-vinyl-2-pyrolidone 
polymer. 
3. Chemical name: 1-ethenyl-2-pyrollidone homo polymer. 
4. Empirical formula: (C6H9NO)n 
5. Molecular weight: 2500-3,000,000 
6. Functional category: 
Disintegrant, dissolution enhancer, suspending agent, tablet binder. 
7. Description: 
Povidone occurs as a fine, white to creamy-white colored, odourless or almost 
odourless, hygroscopic powder. Povidone with equal to or lower than 30 are 
manufactured by spray drying and occurs as spheres. Povidone K90 and higher k-
values manufactured drum drying and occurs as plates. 
8. Incompatibilities: 
Incompatible with in organic salts, natural and synthetic resins. 
9. Application: 
In tablets, Povidone solutions are used as binders in wet granulation processes. 
Povidone is also added to powder blends in the dry form and granulated in situ by the 
addition of water, alcohol or hydro alcoholic solutions. It is used as a solubilizer in 
oral and parenteral formulations. Povidone is used as a coating agent. Povidone is 
additionally used as suspending; stabilizing and viscosity increasing agent in topical 
and oral suspensions and solutions. The solubility of poorly soluble drugs can be 
increased by mixing with povidone. 
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SODIUM BICARBONATE
65 
1. Non-proprietary name: 
  BP: Sodium bicarbonate, JP: Sodium bicarbonate, PhEur: Natrii hydrogeno 
carbonas, USP: Sodium bicarbonate 
2. Synonyms: 
Baking soda, E500, Effer –soda,monosodium carbonate, Sal de vichy, Sodium 
acid carbonate, sodium hydrogen carbonate. 
3. Chemical Name: 
Carbonic acid monosodium salt 
4. Empirical Formula: 
NaHCO3 84.01 
5. Functional Category: 
Alkalizing and therapeutic agents 
6. Description: 
Sodium bicarbonate occurs as an odourless, white, crystalline powder with 
saline, slightly alkaline taste. The crystal structure is monoclinic prisms. 
7. Incompatibilities: 
Reacts with acids, acidic salts and alkaloidal salts 
8. Applications: 
Sodium bicarbonate is used as a source of CO2 in the formulation or 
technology effervescent tablets and granules. In effervescent tablet and granules, 
sodium bicarbonate is usually formulated with citric acid or tartaric acid; tablets 
prepared with sodium bicarbonate alone since the gastric fluid is sufficient to produce 
the effervescences; it is also used in tablet formulations to buffer the drug molecules 
that are weak acids, thereby increasing the rate of dissolution and reducing gastric 
irritation. Recently it is used as a gas generating agent in floating systems and alginate 
raft systems. 
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LACTOSE
65
 
1. Non-proprietary Names: 
BP: Lactose, PhEur: Lactose Monohydrate, USP-NF: Lactose monohydrate 
2. Synonyms: 
CapsuLac, GranuLac, Lactochem; lactosum monohydricum Monohydrate; 
Pharmatose, PrismaLac, SacheLac, SorboLac, SpheroLac, SuperTab 30GR, 
Tablettose. 
3. Chemical Name: O-b-D-Galactopyranosyl-(1-4)-a-D-glucopyranose monohydrate 
4. Empirical Formula: C12H22O11. H2O 
5. Molecular Weight: 360.31 
6. Functional Category: 
Dry powder inhaler carrier, lyophilisation aid, tablet binder, tablet and capsule 
diluents, tablet and capsule filler. 
7. Description: 
The stable crystalline forms of lactose are a-lactose monohydrate, b-lactose 
anhydrous, and stable α -lactose anhydrous. Lactose occurs as white to off-white 
crystalline particles or powder. Lactose is odourless and slightly sweet-tasting; α-
lactose is approximately 20% as sweet as sucrose, while β-lactose is 40% as sweet. 
8. Solubility: 
Practically insoluble in chloroform, ethanol, ether; Soluble in water. 
9. Applications: 
Lactose is widely used as a filler and diluent in tablets and capsules. Lactose is 
also used as a diluent in dry-powder inhalation. Lactose is also used in the 
manufacture of dry powder formulations for use as aqueous film-coating solutions or 
suspensions. Lactose is also used in combination with sucrose (approximately 1: 3) to 
prepare sugar coating solution. 
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MAGNESIUM STEARATE
65 
1. Non-proprietary names: 
BP:Magnesium stearate, JP: magnesium stearate, PhEur:magnesium stearate, 
USP-NF:Magnesium stearate. 
2. Synonyms: 
  Dibasic magnesium stearate, Magnesiudi stearate; Magnesia stearas; 
magnesium  octadecanoate; octadecanoic acid, magnesium  salt; Synpro 90. 
3. Chemical name:  
Octadecanoic acid, Magnesium salt. 
4. Empirical formula: 
  C36H70MgO4 
5. Molecular weight: 
591.24 
6. Functional category: 
Tablet and capsule lubricant. 
7. Description: 
   Magnesium stearate is a very fine, light white, impalpable powder of low bulk 
density, having a faint odour of stearic acid and a characteristic taste. The powder is 
greasy to the touch and readily adheres to the skin. 
8. Incompatibilities: 
Incompatible with strong acids, alkalis and iron salts. 
9. Applications: 
It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0%w/w. It is hydrophobic and may retard the 
dissolution of a drug from solid dosage form. The lowest possible concentration is 
therefore used in such formulations. 
Excipient Profile 
 
Department of Pharmaceutics, Madras Medical College Page 64 
 
 
TARTRAZINE
65 
 
Empirical formula: 
C16H9N4Na3O9S2 
Molecular weight:  
534.39 
CAS number: 
[1934-21-0] 
Synonyms: 
4,5-dihydro-5-oxo-1-(4-sulfophenyl)-4-[(4-sulfophenyl)azo]-1H-pyrazole-3-
carboxylic acid tri sodium salt; E102; FD&C yellow #5; hydrazine yellow. 
Appearance: 
yellow or orange-yellow powder. Aqueous solutions are yellow-colored; the 
color is retained upon addition of hydrochloric acid solution, but with sodium 
hydroxide solution a reddish color is formed. 
Absorption maximum: 
425 nm 
Color Index No.: 
CI 19140 
Use: 
It is used to improve the appearance of a product and to impart a distinctive 
coloring for identification purposes. 
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Table.3: List of materials and their applications in formulation 
S.No Name of material Manufacturer /Supplier 
Use in 
formulation 
1. 
Rosuvastatin 
calcium 
Madras Pharma Pvt.Ltd. Active ingredient 
2. Carvedilol Madras Pharma Pvt.Ltd. Active ingredient 
3. HPMC K 100 Kniss Laborataries 
Hydrophilic 
polymer 
4. 
 
Xanthan gum Kniss Laborataries 
Hydrophilic 
polymer 
5. 
 
Guar gum Kniss Laborataries 
Hydrophilic 
polymer 
 
6. 
 
Sodium starch 
glycolate 
 
KnissLaborataries 
 
Super disintegrant 
 
7. 
 
Crospovidone 
 
KnissLaborataries 
 
Super disintegrant 
 
8. 
 
Croscarmellose 
Sodium 
KnissLaborataries Super disintegrant 
 
9. 
 
PVP K30 
 
KnissLaborataries 
 
Binding agent 
 
10. 
 
Sodium bicarbonate 
 
Indian Research products 
 
Gas generating 
agent 
 
12. 
 
 
Magnesium stearate 
 
 
Indian Research products 
 
Lubricant 
13. Tartrazine Kwality pharmaceuticals Colorant 
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Table 4: List of equipments used 
 
S.No 
 
Equipment’s / Instruments 
 
 
Manufacturer / Supplier 
 
1. 
 
Electronic weighing balance 
 
Asha scientific company, Mumbai 
 
2. 
 
10 Station compression machine 
 
Rimek, India 
 
3. 
 
Vernier calliper 
 
Mitutoyo, Japan 
 
4. 
 
Monsanto hardness tester 
 
Erweka, Mumbai 
 
5. 
 
Friabilator 
 
Electrolab, India 
6. pH meter MC Dalal, Chennai 
 
7. Disintegration apparatus Electrolab, India 
 
8. 
 
Dissolution testing apparatus Veego, India 
9. UV-visible spectrophotometer 1800-Shimadzu, Japan 
10. Fourier Transform Infra-Red 
Spectrophotometer 
Shimadzu, Japan 
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PREFORMULATION STUDIES 
The Preformulation studies are conducted to establish the physiochemical 
characteristics of the drug and its compatibility with the excipients used. The 
Preformulation studies are necessary to formulate drug into stable, safe and effective 
dosage form.  
Drug-excipient compatibility study  
The drug and excipients selected for the formulation are evaluated for physical 
and chemical compatibility studies. 
Physical compatibility study  
The physical compatibility studies are conducted to provide valuable 
information to the formulator in selecting the appropriate excipients for the 
formulation. It was done by mixing the drugs and excipients and placed at room 
temperature, 40°C and 75%RH. Any color change of the physical mixture was 
observed visually.  
Chemical compatibility study
66
 
  Pure drugs, polymers, excipients, drug-excipient mixture was subjected to 
FTIR to investigate the drug-excipient interactions. The IR spectra of test samples are 
obtained using potassium bromide pellet method. 
Potassium bromide pellet method: 
A small amount of finely ground solid sample is intimately mixed with about 
100times its weight of powdered potassium bromide. The finely ground mixture is 
then passed under very high pressure in a press (at least 25,000 psig) to form a small 
pellet(about 1-2 mm thick and 1 cm in diameter). The resulting pellet is transparent to 
IR radiation and is run as such. 
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PREPARATION OF CALIBRATION CURVE:  
Preparation of 0.1N HCl (pH 1.2)
60
:  
8.5 ml of the hydrochloric acid was measured and dissolved 1000 ml of 
distilled water.  
 
Calibration curve forRosuvastatinCalcium
21
 : 
100 mg of Rosuvastatin Calcium was weighed and transferred to a 100ml 
standard flask. The drug was dissolved in 10ml of methanol and made upto 100ml 
using 0.1N HCL in standard flask. From the above solution 10ml was taken and made 
upto 100ml using 0.1N HCL. From the above solution 2ml,4ml, 6ml,8ml,10ml are 
taken and made upto 100ml using 0.1N HCL. The absorbances of resulting solutions 
are measured at 252 nm using UV spectrophotometer. Calibration curve was plotted. 
Calibration curve forCarvedilol
26
 : 
100 mg of  Carvedilol was weighed and transferred to a 100ml standard flask. 
The drug was dissolved in 10 ml of methanol and made up to 100ml using 0.1N HCL 
in standard flask. From the above solution 10ml was taken and made up to 100ml 
using 0.1N HCL. From the above solution 2ml,4ml, 6ml,8ml,10ml are taken and 
made up to 100ml using 0.1N HCL. The absorbances of resulting solutions are 
measured at 241 nm using UV spectrophotometer. Calibration curve was plotted. 
PRECOMPRESSION STUDIES OF DRUGS AND BLENDS: 
FLOW PROPERTY MEASUREMENTS 
The flow properties of powers are critical for an efficient tableting operation. 
A good flow of the powder or granulation to be compressed is necessary to assure 
efficient mixing and acceptable weight uniformity for the compressed tablets. The 
flow property measurements include bulk density, tapped density, angle of repose, 
compressibility index and Hausner’s ratio. The flow property measurements of drugs 
and blends are determined to select the type of granulation to be carried out in the 
formulation. 
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a) BULK DENSITY (ρb)
64 
  It is the ratio of total mass of powder to the bulk volume of powder. It was 
measured by pouring the weighed powder into a measuring cylinder and initial weight 
was noted. This initial volume was called the bulk volume. From this the bulk density 
was calculated according to the formula mentioned below. It is expressed in g/ml and 
is given by 
 
ρb = M/ Vb 
Where, 
M and Vb are mass of powder and bulk volume of the powder respectively. 
b) TAPPED DENSITY(ρt)
64 
 It is the ratio of weight of the powder to the tapped volume of powder. The 
powder was introduced into a measuring cylinder with the aid of funnel and tapped 
for300 times on a wooden surface at a 2 sec interval and the volume attained is the 
tappedvolume. It is expressed in g/ml and is given by 
ρt = M / Vt 
Where,  
M and Vtare mass and tapped volume of the powder respectively. 
c) CARR’S INDEX (OR) % COMPRESSIBILITY64 
It indicates powder flow properties. It is measured for determining the relative 
importance of inter particulate interactions. It is expressed in percentage and is given 
by 
 
                                        CI   =    ρt –ρb X 100  
                                                             ρt 
 
Where, ρt and ρb are tapped density and bulk density respectively. 
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d) HAUSNER RATIO
64 
Hausner’s ratio is an indirect index of ease of powder flow. It is calculated by 
the following formula. 
HR = ρt / ρb 
Where, 
ρt and ρb are tapped density and bulk density respectively. 
e) ANGLE OF REPOSE (θ)64 
 The flow properties were characterized in terms of angle of repose, Carr’s 
index and Hausner’s ratio. For determination of angle of repose (θ), the drug and the 
blend were poured through the walls of a funnel, which was fixed at a position such 
that its lower tip was at a height of exactly 2.0 cm above hard surface. The drug or the 
blends were poured till the time when upper tip of the pile surface touched the lower 
tip of the funnel. Angle of repose was calculated using following equation. 
θ = tan-1(h/r) 
Where, 
h = height of pile in cm; r = radius of pile in cm 
Table 5: Values of Angle of Repose, Compressibility Index and Hausner’s 
Ratio
64 
Flow 
Property 
Angle ofRepose 
(in degrees) 
Compressibility 
Index (%) 
Hausner’s 
Ratio 
Excellent 25-30 <10 1.00-1.11 
Good 31-35 11-15 1.12-1.18 
Fair 36-40 16-20 1.19-1.25 
Passable 41-45 21-25 1.26-1.34 
Poor 46-55 26-31 1.35-1.45 
Very poor 56-65 32-37 1.46-1.59 
Very very 
Poor 
>65 >38 >1.60 
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FORMULATION DEVELOPMENT 
 Formulation of Immediate release tablets of Rosuvastatin Calcium
44 
The immediate release tablets of Rosuvastatin Calcium  (R1, R2 and R3) 
wereprepared by direct compression technique, using various super disintegrants such 
as Sodium Starch Glycolate (SSG), Croscarmellose Sodium (CCS) and Crospovidone. 
The tablets were prepared by using 10 station tablet compression machine. 
Table.6:Formulation table for immediate release tablet of Rosuvastatin Calcium  
 
S.No. 
 
INGREDIENTS 
 
 
R1 
 
R2 
 
R3 
1. Rosuvastatin Calcium 10 10 10 
2. Sodium starch glycolate 4 - - 
3. Crospovidone - 5 - 
4. Croscarmellose sodium - - 2 
5. PVP K30 3 3 3 
6. Lactose 80 79 82 
7. Magnesium stearate 3 3 3 
 
Total weight of the tablet = 100 mg 
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Fig.11: Flowchart for formulation of immediate release Rosuvastatin calcium  
tablets 
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Formulation of Carvedilol floating tablets
26 
The controlled release tablets of Carvedilol were prepared by direct 
compression technique. Different polymers such as Xanthan gum, Guar gum and  
HPMC K 100  are used.The concentrations of Xanthan gum and Guar gum were taken 
as variables. The powder blend was compressed by 10 station tablet compression 
machine using 8mm punches. The optimized batch of floating tablets of Carvedilol 
was then compressed with the optimized batch of immediate release Rosuvastatin 
Calcium  tablets to get bilayer tablets. 
 
Table 7: Formulation table for Carvedilol floating tablets 
S.No. Ingredients C1 C2 C3 C4 C5 C6 C7 C8 
1. Carvedilol 25 25 25 25 25 25 25 25 
2. Xanthan gum - - - - 50 60 70 80 
3. Guar gum 50 60 70 80 - - - - 
4. HPMC K 100 100 100 100 100 100 100 100 100 
5. Sodium 
Bicarbonate 
50 50 50 50 50 50 50 50 
6. PVP K30 12 12 12 12 12 12 12 12 
7. Lactose 54 44 34 24 54 44 34 24 
8. Magnesium 
stearate 
9 9 9 9 9 9 9 9 
 
                                             Total weight of the tablet = 300 mg 
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Fig.12 : Flowchart for formulation of Carvedilol floating tablets 
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Fig.13: Flowchart for formulation of bilayer tablets 
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POST COMPRESSION STUDIES 
PHYSICAL PARAMETERS 
1. General appearance: 
The general appearance of the tablets from each formulation batch was 
observed.The general appearance parameters are shape, color, presence or absence of 
odor and taste were evaluated visually. 
2. Uniformity of weight: 
Twenty tablets were selected at a random and weighed individually. The 
averageweight was also measured. The percentage deviation of tablets was calculated 
andcompared with standard specifications. 
Table 8:  Uniformity of weight 
 
 
 
 
 
 
 
3. Thickness and diameter: 
The thickness and diameter was measured to determine the uniformity of size 
and shape. Thickness and diameter of the tablets were measured using Vernier caliper. 
4. Hardness: 
Hardness is defined as the force required for breaking a tablet at diametric 
compression test and it is termed as tablet crushing strength. Hardness of the prepared 
formulations was determined using Monsanto hardness tester. It was expressed in 
kg/cm2 
 
 
 
 
 
S.No 
 
Average weight of tablet 
 
% Deviation 
 
1. 
 
80 mg or less 
 
10 
 
2. 
 
80 to 250 mg 
 
7.5 
 
3. 
 
More than 250 mg 
 
5 
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5. Friability: 
Friability of the prepared formulations was determined by using Rochelle 
Friabilator. Pre-weighed sample of tablets was placed in the friability tester, which 
was then operated for 100 revolutions. Tablets were dedusted and reweighed. The 
friability of the tablets was calculated using the formula mentioned below, 
               Friability = Initial weight of the tablets – Final weight of the tablet 
                                                    Initial weight of the tablets            
6. Disintegration: 
Randomly six tablets were selected from each batch for disintegration test. 
Disintegration test was performed without disc in simulated gastric fluid (37+ 0.50C) 
using United States Pharmacopeia (USP) disintegration apparatus. The mean standard 
deviations (SD) of six tablets were calculated. 
DRUG CONTENT 
I) FOR IR TABLETS CONTAINING ROSUVASTATIN CALCIUM 
Twenty tablets were selected randomly, weighed and finely grinded. An 
accurately weighed quantity of powder equivalent to 10 mg of Rosuvastatin Calcium 
was transferred to a 100 volumetric flask and dissolved in 10 ml of methanol and the 
volume  was made up to the mark with 0.1N HCl. The solution was filtered and 10 ml  
of the filtrate was further diluted with 0.1N HCl in a 100ml volumetric flask. From 
above solution 10ml was taken and diluted with 0.1N HCL in 100 ml flask. The 
absorbance of the resulting solution was measured at 252 nm taking 0.1N HCl as 
blank using UV Visible Spectrophotometer. The concentration was obtained from the 
calibration graph. 
II) FOR FLOATING TABLETS CONTAINING CARVEDILOL 
Twenty tablets were selected randomly, weighed and finely grinded. An 
accurately weighed quantity of powder equivalent to 25 mg of Carvedilol was 
transferred to a 100 volumetric flask and dissolved in 10 ml of methanol and the 
volume was made upto the mark with 0.1N HCl. The solution was filtered and 10 ml 
of the filtrate was further diluted with 0.1N HCl in a 100ml volumetric flask. From 
above solution 10ml was taken and diluted with 0.1N HCL in 100ml flask. The 
absorbance of the resulting solution was measured at 241 nm taking 0.1N HCl as 
blank using UV Visible Spectrophotometer. The concentration was obtained from the 
calibration graph. 
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III) BILAYER FLOATING TABLETS CONTAINING SIMVASTATIN AND 
TELMISARTAN BY SIMULTANEOUS ESTIMATION METHOD
47 
Simultaneous estimation of Rosuvastatin calcium and Carvedilol was carried 
out using UV spectrophotometer. 
PROCEDURE: 
The following equations were used to determine the contents. 
                            Cx  =   A2ay1 – A1ay2 
                                         ax2 ay1-ax1 ay2 
 
                            Cy = A1ax2 – A2ax1 
                                     ax2 ay1-ax1 ay2 
Where, 
ax1 and ax2= the absorptivity of drug X at λ1 and λ2 respectively 
ay1 and ay2= the absorptivity of drug Y at λ1 and λ2 respectively 
            A1 and A2 = the absorbance of sample at λ1 and λ2 respectively 
In 1990, Glen suggested a criterion for obtaining maximum precision, based on 
absorbance ratios
68 
 
                                                A2/A1               and         ay2/ay1 
                                                ax2/ax1                                   A2/A1 
 
The ratios should lie outside the range of 0.1-2.0 for the precise determination 
of X and Y drugs respectively. This criterion is satisfied only when the λ max of the 
two components is reasonably dissimilar and the two components should not interact 
chemically. 
Preparation of standard stock solution of Rosuvastatin Calcium: 
100 mg of  Rosuvastatin calcium was accurately weighed; 10 ml of methanol was 
added and further diluted to 100ml with 0.1N HCl. From above solution 10ml was 
taken and diluted to 100ml with 0.1N HCl. The absorbance of the solution was 
recorded at 252 nm and 241 nm. 
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Preparation of standard stock solution of Carvedilol: 
100 mg of Carvedilol  was accurately weighed; 10 ml of methanol was added 
and further diluted to 100ml with 0.1N HCl. From above solution 10ml was taken and 
diluted to 100ml with 0.1N HCl. The absorbance of the solution was recorded at 252 
nm and 241 nm. 
Preparation of sample solution:  
Twenty tablets were selected randomly and the average weight was calculated. 
The tablets were then ground to a fine powder. The powder equivalent to the average 
weight of tablets was dissolved in 20 ml of methanol. The solution was made up to 
100 ml with 0.1N HCL. 10 ml of the solution was diluted to 100 ml using 0.1N HCL 
in a separate standard flask. The absorbance of the solution was recorded at 252 nm 
and 241 nm. The amount of Rosuvastatin Calcium and Carvedilol were determined by 
simultaneous estimation method. 
IN-VITRO DISSOLUTION STUDIES: 
For IR tablets: 
The release of Rosuvastatin calcium was determined using USP Type II 
(Paddle) dissolution apparatus under sink condition. The dissolution medium was 900 
ml of a0.1N HCl solution (pH=1.2), at 370c±0.20c and the stirring speed of 50 rpm. 
The in-vitro release studies were carried out for 1 hour. The absorbance of the 
solution was recorded at 291 nm using UV spectrophotometer. 
For bilayer floating tablets: 
The release of Rosuvastatin calcium and Carvedilol was determined using 
USP Type II(Paddle) dissolution apparatus under sink condition. The dissolution 
medium was 900 ml of a 0.1N HCl solution (pH=1.2), at 370c±0.20c and the stirring 
speed of 100 rpm. Aliquot(10ml) of the solution was collected from the dissolution 
medium at 5,10,15, 20, 30,45 min and at1,2,3,4,5,6,7,8,9,10,11,12 and 24 hours and 
were replaced with fresh dissolution medium.The absorbance of the solution was 
recorded at 252nm and 241 nm using UV spectrophotometer. 
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SWELLING STUDIES OF  FLOATING TABLETS
20
: 
The extent of swelling was measured in terms of percentage weight gain by 
tablets. The swelling behaviour of  all the floating tablets  was studied. Swelling index 
was determined in 900 ml of 0.1N HCl solution(pH=1.2), at 37
0
c±0.5
0
c. At the end of 
1,2,3,4,5,6,7,8,910,11,12 and 24 hours. Tablets were withdrawn and the excess of 
fluid was removed with a tissue paper. The tablets were weighed. The percentage 
weight gain by the tablet was calculated using the formula. 
 
SI= Mt-M0     × 100 
                                                               M0 
Where, 
  SI= Swelling index 
Mt= Weight of tablet at time t and 
M0= Weight of tablet at time 0 
EVALUATION OF IN-VITRO RELEASE KINETICS
76
: 
To study the in-vitro release kinetics of the optimized BFT, data obtained from 
dissolution study were plotted in various kinetics models. 
1. Zero order equation : 
The zero order release can be obtained by plotting cumulative % percentage 
drug released vs. time in hours. It is ideal for the formulation to have release profile of 
zero order to achieve pharmacological prolonged action. 
C=K0t 
Where, 
K0= Zero order constant 
               t= Time in hours 
2. First order equation: 
The graph was plotted as log % cumulative drug remaining Vs time in hours. 
Log C= log C0- Kt/2.303 
Where, 
 C0= Initial concentration of drug 
K= First order 
t= Time in hours 
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3. Higuchi kinetics: 
The graph was plotted with % cumulative drug released vs. square root of time 
Q = Kt
½
 
Where, 
K= constant reflecting design variable system (differential rate constant) 
t= Time in hours 
The drug release rate is inversely proportional to the square root of time 
4. Hixon and Crowell erosion equation: 
To evaluate the drug release with changes in the surface area and the diameter 
of particles, the data were plotted using the Hixon and Crowell rate equation. The 
graph was plotted by cube root of % drug remaining vs. time in hours. 
Q0
1/3
 – Qt1/3 = KHCXt 
Where, 
Qt= amount of drug released in time t. 
Q0= Initial Amount of drug 
KHC= Rate constant for Hixon Crowell equation 
5. Korsmeyer-Peppas equation: 
To evaluate the mechanism of drug release, it was further plotted in Peppas 
equation as log cumulative % of drug released Vs log time. 
Mt/Mα = Kt
n
 
Where 
Mt/Mα = Fraction of drug released at time t 
t = Release time 
K= Kinetics constant (Incorporating structural and geometric characteristics of 
the formulation) 
N= Diffusional exponent indicative of the mechanism of drug release. 
Table9: Diffusion exponent and solute release mechanism for cylindrical shape 
Diffusion exponent (n) Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45 < n < 0.89 Anomalous (non- Fickian) diffusion 
0.89 Case II transport 
n > 0.89 Super case II transport 
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PREFORMULATION STUDIES: 
DRUG-EXCIPIENT COMPATIBILITY STUDY: 
The drug-excipient compatibility study was conducted to reveal the excipient compatibility 
with the drug. The physical compatibility of drug and excipients were given in table 10. 
Table 10: Physical compatibility study of Drug and Excipients 
 
S. 
No. 
Description and Conditions 
Drug & Excipient 
Initial 
 
Room 
temperature and 
400C/ 75% RH 
in days 
10 20 30 
1 ROS Creamish white crystalline powder NC NC NC 
2 CAR White crystalline powder NC NC NC 
3 Xanthan gum Creamy white Free flowing fine powder NC NC NC 
4 Guar gum White or creamy white Free flowing fine 
powder 
NC NC NC 
5 HPMC K 100 White or creamy white crystalline powder NC NC NC 
6 PVPK30 
White or Creamy white colored 
Hygroscopic powder 
NC NC NC 
7 Sodium bicarbonate White, crystalline powder NC NC NC 
8 Magnesium Stearate White or off white crystalline powder NC NC NC 
9 Tartrazine Yellowish orange coloured powder NC NC NC 
10 CAR + Xanthan gum White, creamy white crystalline powder NC NC NC 
11 CAR+ Guar gum White, creamy white crystalline powder NC NC NC 
12 CAR+ HPMC K 100 White, creamy white crystalline powder NC NC NC 
13 CAR+ PVPK30 White, almost white crystalline powder NC NC NC 
14 
CAR+ Sodium 
Bicarbonate 
White, almost white crystalline powder NC NC NC 
15 
CAR+ Magnesium 
Stearate 
White, almost white crystalline powder NC NC NC 
16 
        
        ROS+ CCS 
 
White, creamy white crystalline powder NC NC NC 
17 ROS+CP White, creamy white crystalline powder NC NC NC 
NC- No Change 
The physical compatibility study was performed visually. The study implies that the 
drug and excipients were physically compatible with each other as there was no change in 
physical description.  
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CHEMICAL COMPATIBILITY STUDY 
 
The possible interaction between the drug and the excipients used in the 
formulation was studied by FTIR spectroscopy. The results are given in the below 
 
         FTIR SPECTROSCOPY OF DRUGS 
 
 
Fig 15: FTIR of Rosuvastatin Calcium. 
 
                  Table 11: IR Spectral interpretation of Rosuvastatin Calcium 
Wave number (cm
-1
) Interpretation 
3395 N-H Stretching 
3200 -3550 O- H Stretching 
3080 C-H Aromatic Phenol 
2970 Alkane C-H Stretching 
2873 Aldehyde C-H Stretching 
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Fig 16: FTIR of Carvedilol. 
 
Table 12: IR Spectral interpretation of Carvedilol. 
 
Wave number (cm
-1
) Interpretation 
3345 N-H Stretching 
2502 Carboxylic acid O-H Stretching 
3059 Aromatic C-H 
2964 Alkane C-H Stretching 
2876 Aldehyde C-H Stretching 
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FTIR SPECTROSCOPY OF ROSUVASTATIN CALCIUM AND EXCIPIENTS 
 
 
 
 
 
Fig 17: FTIR Spectroscopy of Rosuvastatin CalciumSodium Starch Glycolate (SSG) 
 
Table 13: IR Spectral interpretation of Rosuvastatin Calcium with Starch Glycolate 
Wave number (cm
-1
) Interpretation 
3345 N-H Stretching 
2502 Carboxylic acid O-H Stretching 
3059 Aromatic C-H 
2964 Alkane C-H Stretching 
2876 Aldehyde C-H Stretching 
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Fig 18: FTIR Spectroscopy of Rosuvastatin Calcium with Crospovidone 
 
Table 14: IR Spectral Interpretation of Rosuvastatin Calcium with Crospovidone 
 
Wave number (cm
-1
) Interpretation 
3345 N-H Stretching 
2502 Carboxylic acid O-H Stretching 
3059 Aromatic C-H 
2964 Alkane C-H Stretching 
2876 Aldehyde C-H Stretching 
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Fig 19: FTIR Spectroscopy of Rosuvastatin Calcium with Croscarmellose Sodium 
(CCS) 
Table 15: IR Spectral interpretation of Rosuvastatin Calcium with Croscarmellose 
sodium 
Wave number (cm
-1
) Interpretation 
3345 N-H Stretching 
2502 Carboxylic acid O-H Stretching 
3059 Aromatic C-H 
2964 Alkane C-H Stretching 
2876 Aldehyde C-H Stretching 
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FTIR SPECTROSCOPY OF CARVEDILOLAND EXCIPIENTS 
 
 
 
 
 
 
 
Fig 20: FTIR of Carvedilol with Xanthan gum 
 
Table 16: IR Spectral interpretation of Carvedilol with Xanthan gum 
Wave number (cm
-1
) Interpretation 
3345 N-H Stretching 
2502 Carboxylic acid O-H Stretching 
3059 Aromatic C-H 
2964 Alkane C-H Stretching 
2876 Aldehyde C-H Stretching 
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                                          Fig 21: FTIR of Carvedilol with Guar Gum 
 
Table 17: IR Spectral interpretation of Carvedilol with Guar Gum 
Wave number (cm
-1
) Interpretation 
3345 N-H Stretching 
2502 Carboxylic acid O-H Stretching 
3059 Aromatic C-H 
2964 Alkane C-H Stretching 
2876 Aldehyde C-H Stretching 
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Fig 22: FTIR of Carvedilol with HPMC K 100 
 
 
Table 18: IR Spectral Interpretation of Carvedilol with HPMC K 100 
 
Wave number (cm
-1
) Interpretation 
3345 N-H Stretching 
2502 Carboxylic acid O-H Stretching 
3059 Aromatic C-H 
2964 Alkane C-H Stretching 
2876 Aldehyde C-H Stretching 
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Fig 23: FTIR of Rosuvastatin Calcium powder blend 
 
Table 19: IR Spectral Interpretation of Rosuvastatin calcium powder blend. 
 
Wave number (cm
-1
) Interpretation 
3345 N-H Stretching 
2502 Carboxylic acid O-H Stretching 
3059 Aromatic C-H 
2964 Alkane C-H Stretching 
2876 Aldehyde C-H Stretching 
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Fig 24: FTIR of Carvedilol  powder blend 
Table 19: IR Spectral Interpretation of Carvedilol powder blend 
 
Wave number (cm
-1
) Interpretation 
3345 N-H Stretching 
2502 Carboxylic acid O-H Stretching 
3059 Aromatic C-H 
2964 Alkane C-H Stretching 
2876 Aldehyde C-H Stretching 
 
 
The spectra indicated that there was no drug – excipient interaction as the peaks of 
the drug and the other excipients were seen in the drug excipient mixture. The study   impliesthat 
the active ingredients and the excipients are chemically compatible with each other as there was 
no change in the IR spectral peaks. 
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CALIBRATION CURVE FOR ROSUVASTATIN CALCIUM 
Table. 20: Data of calibration curve Rosuvastatin Calcium in 0.1N HCl 
 
Concentration 
(μg/mL) 
 
 
Absorbance at λ252nm 
0 0 
2 0.064±0.0019 
4 0.128±0.0053 
6 0.190±0.0024 
8 0.249±0.0094 
10 0.319±0.0054 
 
                                                                                    Mean   n=3  R
2
=0.9998 
 
 
Fig.25:Calibration curve of Rosuvastatin Calcium 
            It was found that the solutions of Rosuvastatin calcium in 0.1 N HCl shows linearity 
        (R2=0.9998) in absorbance at concentrations of 2-10 μg/ml and obey beer Lambert’s Law. 
 
y = 0.0316x + 0.0003 
R² = 0.9996 
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CALIBRATION CURVE FOR  CARVEDILOL 
Table.21:Data of calibration curve of Carvedilolin 0.1 N HCl. 
 
 
                                                                                              R
2
=0.9998 
 
 
 
Fig.26: Calibration curve of Carvedilol 
It was found that the solutions of Carvedilol in 0.1 N HCl show linearity(R2=0.9998) in 
absorbance at concentrations of 2-10 μg/ml and obey Beer Lambert’s Law. 
y = 0.1183x - 0.0088 
R² = 0.9997 
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Concentration 
(μg/ml) 
Absorbance at λ241nm 
0 0 
2 0.218  ±0.0097 
4 0.469  ±0.0063 
6 0.691  ±0.0032 
8 0.940  ±0.0038 
10 1.179  ±0.0233 
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FOR IR FORMULATION: 
PRECOMPRESSION  STUDIES: 
The drug and the powder  blends are evaluated for Precompression parameters. The 
results are given in the table. 
Table.22:Precompression studies of drug and the powder blends without glidant 
Drug 
Formulation 
Bulk 
density* 
g/cm
3
 
Tapped 
density* 
g/cm
3
 
Compressibility 
index*(%) 
Hausner’s 
ratio* 
Angle of 
repose* 
(degree) 
Rosuvastatin 
Calcium 
0.652±0.019 0.750± 0.025 13.08±0.438 1.15±0.0056 9.54±1.360 
R1 0.511±0.026 0.594±0.016 13.99±1.995 1.163±0.026 35.22±0.02 
R2 0.501±0.011 0.612±0.017 18.10±0.419 1.22±0.0061 33.53±1.09 
R3 0.570±0.010 0.646±0.012 11.76±0.010 1.13±0.0053 27.54±0.02 
The bulk density of  the drug and IR Blends without lubricant ranged from  0.501 to 
0.652 g/cm3and tapped density ranged from 0.594 to 0.750 g/cm3. The compressibility index of 
the drug and IR blend ranged from 11.76 to 18.10 % and Hausner’s ratio ranged from 1.13 to 
1.22. The angle of repose of IR blends ranged from 9.54 to 35.22. The formulated blends showed  
fair to good flow property. 
Table .23:Precompression study of powder blend with lubricant of immediate release 
layer: 
Drug 
Formulation 
Bulk 
density* 
g/cm3 
Tapped 
density* 
g/cm3 
Compressibility 
index*(%) 
Hausner’s 
ratio* 
Angle of 
repose* 
(degree) 
R1 0.570±0.021 0.646±0.013 11.76±0.011 1.13±0.018 34.25±1.32 
R2 0.544±0.026 0.612±0.017 11.11±0.032 1.125±0.025 31.41±0.22 
R3 0.612±0.01 0.698±0.022 12.21±0.35 1.14±0.0047 27.10±0.57 
 
The bulk density of IR Blends ranged from 0.544 to 0.612 g/cm3and tapped densityranged 
from 0.612 to 0.698 g/cm3. The compressibility index of the IR blends ranged from11.11to 
12.21% and Hausner’s ratio ranged from1.125 to1.14. The angle of repose of IRblends ranged 
from 27.10 to 34.25. The formulated IR blends with the addition of lubricant showed good 
flowproperty. 
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POST COMPRESSION STUDY 
UNIFORMITY OFWEIGHT: 
         The uniformity of weight of the formulated tablets is given in the table  
                           Table.24: Uniformity of weight of the formulated tablets 
 
                                                                          *MEAN±S.D (n=20) 
The tablets comply with the test for uniformity of weight
60
. 
TABLET THICKNESS AND DIAMETER: 
The thickness and diameter of the formulated tablets is given in the table 25. 
Table.25: Thickness and Diameter of the formulated tablets 
Formulation Thickness* 
(mm) 
Diameter* 
(mm) 
R1 2.00 ± 0.00 6.00 ± 0.00 
R2 2.00 ± 0.00 6.00 ± 0.00 
R3 2.00 ± 0.00 6.00 ± 0.00 
                                                                                                      *MEAN±S.D (n=05) 
 
The thickness and diameter of the tablets were found to be 2 mm and 6 mm 
respectively. The tablets have uniform thickness and diameter. 
  
Formulation Uniformity of weight(mg)* 
R1 99.21 
R2 97.80 
R3 98.26 
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HARDNESS: 
 The hardness of the formulated tablets is given in the table 26. 
Table.26: Hardness of the formulated tablets 
Formulation Hardness* 
Kg/cm
2
 
R1 2.50 ±0.00 
R2 2.15±0.210 
R3 2.20±0.244 
                                                                                    *MEAN±S.D (n=05) 
 
The hardness of the tablets was found to be between 2.15 kg/cm
2
 and 2.50 kg/cm
2
. 
 
FRIABILITY: 
The Friability of the formulated tablets is given in the table 27 
Table.27: Friability of the formulated tablets 
Formulation Friability (%)* 
R1 0.872 ±0.030 
R2 0.934 ±0.021 
R3 0.825 ±0.024 
                                                                                   *MEAN±S.D (n=03) 
 
The percentage friability of the tablets ranged from 0.825 % to 0.934 %. Hence the 
percentage friability complies with the official standard
60
. 
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DRUG CONTENT: 
The Drug content of the formulated IR tablets is given in the table 28 and Fig.27 
Table.28: Drug content of the formulated IR tablets 
 
 
                                                              MEAN±S.D (n=03) 
 
                                                                                    
 
 
Fig.27: Drug content of the formulated IR tablets 
The percentage drug content of all the formulations ranged from 94.19 % w/w to 
to 106.20 % w/w60 
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DISINTEGRATION TIME: 
The disintegration time of the IR tablets is given in the table 
Table.29: Disintegration time of the IR tablets 
Formulation Disintegration 
time(seconds) 
R1 297 
R2 35 
R3 23 
 
 
 
Fig.28 : Disintegration time of the IR tablets 
 
                        The Disintegration time of all the formulations were ranged from 23 to 297 sec. 
The Formulation R3 disintegrated within 23 sec. 
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IN-VITRO DISSOLUTION STUDY: 
The in-vitro dissolution of immediate release formulations of Rosuvastatin Calciumis 
given inthe Table.30  and Fig.29 
 
Table.30:In-vitro dissolution of immediate release formulation of Rosuvastatin Calcium 
 
Time in Minutes 
 
 
Cumulative % drug release* 
R1 R2 R3 
5 19.68 ± 0.344 75.34 ±0.476 80.86 ± 0.537 
10 31.35 ±0.256 86.79 ±0.237 92.79 ±0.476 
15 48.06 ±0.273 92.79 ±0.569 99.36 ± 0.582 
20 64.85 ±0.468 98.80 ±0.594  
30 70.74 ±0.449   
40 82.16 ±0.126   
50 99.13 ±0.528   
60 105.19 ±0.483   
                                                                        *MEAN±S.D (n=3) 
 
Fig.29 :In-vitro dissolution of immediate release formulation of Rosuvastatin calcium 
From the invitro dissolution study the formulation R3 was found optimum and 
selected for bilayer floating tablets. 
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FOR FLOATING TABLETS: 
PRECOMPRESSION STUDY: 
The drug and the formulated blends of floating Carvedilol were evaluated for 
Precompression parameters. The results are given in the table 31. 
 
Table Precompression study of drug and formulated blends without lubricant 
Drug 
formulation 
Bulk 
density* 
g/cm3 
Tapped 
density* 
g/cm3 
Compressibility 
index*(%) 
Hausner’s 
ratio* 
Angle of 
repose* 
(degree) 
Carvedilol 0.230±0.0073 0.268±0.0056 13.93 ±1.58 1.16±0.021 13.27 ±0.145 
C1 0.500±0.011 0.666±0.010 24.92±1.92 1.33±0.028 35.25±1.05 
C2 0.535±0.013 0.666±0.023 19.56±2.05 1.25±0.032 30.35±2.57 
C3 0.526±0.021 0.666±0.018 21.06±1.39 1.26±0.025 35.39±1.22 
C4 0.500±0.011 0.652±0.019 23.28±2.31 1.30±0.037 36.32±1.23 
C5 0.492±0.113 0.652±0.019 24.56±0.509 1.32±0.009 43.32±0.654 
C6 0.500±0.015 0.652±0.02 23.28±2.31 1.30±0.03 40.07±0.753 
C7 0.492±0.011 0.666±0.016 25.12±1.70 1.33±0.03 39.39±0.655 
C8 0.508±0.017 0.666±0.010 23.62±1.84 1.31±0.03 40.13±0.269 
*MEAN±S.D (n=3) 
 
The bulk density of drug and  CR blend ranged from 0.230to 0.535 g/cm3and tapped 
density ranged from 0.268 to 0.666 g/cm3. The compressibility index of the CR blend ranged 
from 13.93 to 25.12% and Hausner’sratio ranged from1.16 to1.33. The angle of repose of CR 
blend ranged from 13.27 to 43.32. The formulated CR blend  showed fair to  good flow property. 
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Table 32.Precompression study of drug and formulated blends with lubricant 
Drug 
formulat
ion 
Bulk 
density* 
g/cm3 
Tapped 
density* 
g/cm3 
Compressibili
ty 
index*(%) 
Hausner’s 
ratio* 
Angle of 
repose* 
(degree) 
C1 0.526±0.023 0.666±0.016 21.02±0.019 1.27±0.028 33.11±0.75 
C2 0.588±0.037 0.714±0.026 17.64±0.031 1.21±0.045 33.43±1.27 
C3 0.526±0.015 0.625±0.030 15.84±0.038 1.19±0.041 33.50±0.59 
C4 0.500±0.011 0.625±0.024 20.13±0.016 1.25±0.053 33.26±1.56 
C5 0.535±0.013 0.638±0.010 16.11±0.386 1.19±0.004 41.34±0.378 
C6 0.535±0.010 0.638±0.020 16.12±0.390 1.19±0.004 38.14±0.452 
C7 0.526±0.025 0.638±0.027 17.57±2.440 1.22±0.040 38.46±1.10 
C8 0.526±0.036 0.625±0.012 15.84±0.032 1.19±0.028 37.41±0.695 
                                                                                                                    *MEAN±S.D (n=3) 
 
 
The bulk density of drug and  CR blend ranged from 0.500to 0.588 g/cm3and tapped 
density ranged from 0.625 to 0.714 g/cm3. The compressibility index of the CR blend ranged 
from 13.93 to 25.12% and Hausner’s ratio ranged from1.16 to1.33. The angle of repose of CR 
blend ranged from 13.27 to 43.32. The formulated CR blend  showed fair to  good flow property. 
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POST COMPRESSION STUDIES OF CARVEDILOL FLOATING TABLETS: 
UNIFORMITY OF WEIGHT: 
The uniformity of weight of the floating tablets is given in the table 33. 
Table.33: Uniformity of weight of the floating tablets 
Formulation    Uniformity of weight(mg)* 
C1 297.82 
C2 297.80 
C3 297.51 
C4 297.90 
C5 297.16 
C6 297.60 
C7 297.82 
C8 297.96 
*MEAN±S.D (n=20) 
The tablets comply with the test for uniformity of weight60. 
TABLET THICKNESS AND DIAMETER: 
The thickness and diameter of the floating tablets is given in the table34 . 
Table.34 : Thickness and Diameter of the floating tablets 
Formulation Thickness* (mm) Diameter* (mm) 
C1 3.00±0.00 9.00±0.00 
C2 3.00±0.00 9.00±0.00 
C3 3.00±0.00 9.00±0.00 
C4 3.00±0.00 9.00±0.00 
C5 3.00±0.00 9.00±0.00 
C6 3.00±0.00 9.00±0.00 
C7 3.00±0.00 9.00±0.00 
C8 3.00±0.00 9.00±0.00 
*MEAN±S.D (n=5) 
The thickness and diameter of the tablets were found to be 3 mm and 9 mm 
respectively. The tablets have uniform thickness and diameter. 
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HARDNESS: 
The hardness of the floating tablets is given in the table35. 
Table.35: Hardness of the floating tablets 
Formulation Hardness* Kg/cm
2
 
C1 3.3±0.244 
C2 3.9±0.21 
C3 4.1±0.20 
C4 4.1±0.20 
C5 3.5±0.12 
C6 3.9±0.20 
C7 4.2±0.28 
C8 4.3±0.31 
*MEAN±S.D (n=5) 
The hardness of the tablets was found to be between 3.3 kg/cm2and 4.3 kg/cm2 
FRIABILITY: 
The Friability of the floating tablets is given in the table36. 
Table.36: Friability of the floating tablets 
Formulation Friability* (%) 
C1 0.249± 0.0095 
C2 0.228±0.0057 
C3 0.203±0.0046 
C4 0.194±0.0098 
C5          0.235±0.0078 
C6 0.212±0.0068 
C7 0.198±0.0074 
C8 0.187±0.0057 
*MEAN±S.D (n=3) 
The percentage friability of the tablets ranged from 0.187 % to 0.249 %. Hence 
thepercentage friability complies with the official standard. 
 
Results and Discussions 
 
Department of Pharmaceutics,Madras Medical College. Page 105 
 
INVITRO FLOATING STUDIES: 
The invitro floating characteristics of Carvedilol floating tablets is given in the 
Table37  and Fig 30 
                  Table.37 :In-vitro floating characteristics of Carvedilol floating tablets 
Formulation Floating lag time 
(seconds) 
Floating duration 
(Hours) 
C1 42 >24 
C2 51 >24 
C3 48 >24 
C4 45 >24 
C5 73 >24 
C6 69 >24 
C7 75 >24 
C8 72 >24 
*MEAN±S.D (n=3) 
 
Fig.30 :In-vitro floating lag time of Floating tablets 
The floating duration of all floating tablets was  >24 hours and the floating lag time 
ranged from 42 –85 seconds. 
 
 
0
10
20
30
40
50
60
70
80
C1 C2 C3 C4 C5 C6 C7
Ti
m
e
 in
 s
e
co
n
d
s 
Formulation 
FLOATING LAG TIME (SECONDS) 
Floating lag time (seconds)
Results and Discussions 
 
Department of Pharmaceutics,Madras Medical College. Page 106 
 
DRUG CONTENT: 
 
The drug content of Carvedilol floating tablets is given in the table38  and Fig 31. 
Table.38: Drug content of floating tablet 
Formulation % Drug content  
C1 97.82 
C2 96.92 
C3 101.6 
C4 98.20 
C5 97.96 
C6 102.68 
C7 99.74 
C8 98.96 
 
 
Fig.31: Drug content for formulated floating Carvedilol tablets 
The percentage drug content of Carvedilolin all the formulations rangedFrom 96.92 % 
w/w to 102.68% w/w . All the formulations comply with the officialStandards
60
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SWELLING STUDIES OF CARVEDILOL FLOATING TABLETS: 
 
Swelling study was carried out on the bilayer floating tablets. The % swelling of 
the bilayer floating tablets is given in the table 39 and fig. 32 
 
Table 39: Swelling Index of Carvedilol floating tablets 
Time 
in 
hours 
% Swelling 
 
C1 
 
C2 
 
C3 
 
C4 
 
C5 
 
C6 
 
C7 
 
C8 
0 0 0 0 0 0 0 0 0 
1 42.73 45.01 47.28 48.23 34.17 35.61 35.98 37.56 
2 91.69 92.73 92.85 94.32 87.72 89.46 89.57 90.85 
4 156.48 156.72 158.79 159.47 140.52 142.36 146.02 148.83 
6 183.61 183.83 185.30 186.49 175.21 176.96 178.59 178.82 
8 221.05 224.76 226.83 227.90 209.31 216.89 217.23 219.83 
10 268.74 269.23 269.58 272.34 274.82 279.31 282.73 284.67 
12 304.72 305.73 309.56 314.59 297.72 299.56 301.58 305.67 
 
The swelling index of the Carvedilol floating tablets showed that the floating matrix layer 
maintained their integrity and increased swelling during the study.The swelling index of the 
Carvedilol floating tablets ranged from 297.72 to 314.59%.  
 
Fig. 32: Swelling index of Carvedilolfloating tablets. 
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IN VITRO DISSOLUTION STUDY: 
The in-vitro dissolution of Carvedilol floating tablets is given in the table.40  and 
fig.33 
Table.40:In-vitro dissolution study of Carvedilol floating tablets 
TIME 
(Hours) 
CUMULATIVE % DRUG RELEASE 
C1 C2 C3 C4 C5 C6 C7 C8 
1 11.41 9.92 7.66 6.35 10.43 9.86 8.66 7.206 
2 14.67 12.49 10.69 8.98 16.08 1.43 13.08 11.60 
3 17.96 16.32 14.34 13.56 20.52 15.85 16.32 14.74 
4 21.91 20.18 18.01 17.52 28.08 20.64 20.17 19.12 
5 25.87 23.42 20.51 20.86 33.83 25.44 24.05 22.30 
6 34.35 27.32 25.40 24.86 38.98 29.69 27.95 26.11 
7 38.39 29.95 27.33 27.59 46.65 33.96 31.24 29.33 
8 44.36 34.52 31.68 31.62 51.25 38.26 35.81 31.94 
9 49.73 39.73 34.84 33.69 55.87 43.16 38.52 34.58 
10 55.77 45.60 38.62 36.51 59.53 48.17 43.12 37.84 
11 59.92 50.23 43.01 38.65 64.31 54.28 48.37 41.12 
12 64.72 56.16 48.64 40.81 66.44 61.53 56.17 48.11 
18 75.28 61.52 53.75 44.97 77.46 68.27 64.32 51.05 
19 78.93 63.84 55.46 45.54 80.98 69.34 66.79 52.78 
20 80.45 65.27 56.37 46.53 84.14 71.03 67.48 54.94 
21 82.57 67.35 58.68 47.48 87.71 74.89 68.04 56.38 
22 84.36 68.60 60.94 49.38 90.67 76.56 68.95 57.50 
23 86.97 70.38 62.59 50.49 94.88 79.30 70.38 58.03 
24 87.52 72.16 63.86 52.04 97.25 80.65 71.54 58.70 
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Fig.33 :In-vitro dissolution study of Carvedilol floating tablets 
 
The results of invitro dissolution study of Gastroretentive floating tablets showed that 
all the formulations containing guar gum,xanthan gum and HPMC K 100 controlled the drug 
release more than 24 hours. Among these formulations C5 formulation containing xanthan 
gum polymer releases 97.25% at the end of 24 hrs. From above results the formulation C5 
was found optimum and selected for bilayer floating tablets. 
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FORMULATION OF BILAYER FLOATING TABLETS 
The optimized immediate release powder blend (R3) was compressed on the 
optimized floating powder blend (C5) using 10 station tablets compression machine. 
 
POST COMPRESSION STUDY OF BILAYER FLOATING TABLETS 
 
The compressed bilayer floating tablets were evaluated for the following parameters 
and values are given in table below. 
 
Table41: Post compression study of bilayer tablets 
PARAMETERS BILAYER TABLETS 
Uniformity of weight (mg) 400.06 ± 0.109 
Thickness (mm) 4.00 ± 0.00 
Diameter (mm) 9.00 ± 0.00 
Hardness (kg/cm2) 6.36 ± 0.210 
Friability (%) 0.267±0.0056 
Floating lag time (secs) 78 
Floating duration (hours) >24 
 
% Drug content 
Rosuvastatin 
calcium 
98.61 
Carvedilol 97.28 
 
                       The bilayer floating tablets fulfilled the official requirement of uniformity of 
weight, thickness, diameter, hardness, friability and drug content was found to be within the 
limit60. 
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IN-VITRO DRUG RELEASE STUDY OF BILAYER TABLETS 
The in-vitro dissolution study of bilayer floating tablets is given in table .42 
Table.42: In-vitro dissolution study of bilayer floating tablets 
 
TIME 
(Hours) 
CUMULATIVE % DRUG RELEASE 
Rosuvastatin calcium Carvedilol 
0.083 61.71 - 
0.16 81.87 - 
0.25 99.97 - 
0.33 107.13 - 
0.41  - 
0.5  1.03 
0.75  2.97 
1  7.47 
2  13.3 
3  21.73 
4  25.71 
5  33.23 
6  38.55 
7  46.14 
8  51.22 
9  56.64 
10  61.77 
11  67.25 
12  69.54 
18  71.28 
19  78.74 
20  83.03 
21  86.69 
22  88.12 
23  90.84 
24  98.09 
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Fig.34:In-vitro drug release study of bilayer floating tablets 
 
 
 
 
 
Fig. 35: Bilayer Tablets 
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IN-VITRO RELEASE KINETICS: 
The values obtained from invitro dissolution of from Carvedilol bilayer floating 
tablet were fitted in various kinetic models. 
Table.43 : In-vitro Release Kinetics of BFT 
Time 
in 
Hours 
% 
Cum. 
Drug 
release 
Log% 
cum. 
Drug 
release 
Square 
root of 
time 
Log 
time 
% Cum. 
Drug 
remaining 
Log% 
Cum. 
drug 
remaining 
Cube root 
of % drug 
remaining 
0 0 -∞ 0 -∞ 100 2 4.641 
1 11.06 1.043 1 0 88.94 1.949 4.463 
2 15.46 1.189 1.414 0.301 84.54 1.927 4.388 
3 21.14 1.325 1.732 0.477 78.86 1.896 4.288 
4 26.84 1.428 2 0.602 73.16 1.864 4.182 
5 32.58 1.551 2.236 0.698 67.42 1.828 4.070 
6 38.36 1.583 2.449 0.778 61.64 1.789 3.950 
18 76.46 1.883 4.242 1.255 23.54 1.371 2.865 
19 79.98 1.902 4.358 1.278 20.02 1.301 2.715 
20 84.14 1.925 4.472 1.301 15.86 1.200 2.512 
21 87.71 1.943 4.582 1.322 12.29 1.089 2.307 
22 90.67 1.957 4.690 1.342 9.33 0.969 2.105 
23 94.88 1.977 4.795 1.361 5.12 0.709 1.723 
24 97.25 1.987 4.898 1.380 2.75 0.439 1.401 
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Fig.36: Zero order release kinetics 
 
       
Fig. 37:First order release kinetics 
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Fig.38: Higuchi kinetics 
 
                       
 
Fig.39: Hixson crowell cube root kinetics 
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Fig. 40:Korsemeyerpeppas kinetics 
Determination of drug release mechanism of bilayer floating tablets: 
The co-efficient of determination(R
2
)  was taken as criteria for the conclusion of 
kinetic modelling. The R
2 
 values of  various kinetic models are given in the table 44. 
Table 44: R
2 
 values of various kinetic models 
Kinetic model co-efficient of  determination(R
2
) 
Zero order 0.990 
First order 0.903 
Higuchi 0.970 
Hixon- Crowell 0.966 
Korsmeyer and Peppas 0.995 
 

The order of release of drug was found to be zero order, in which R2 value was close to 1  
The n value of Korsmeyer Peppas equation was found to be0.699, from that it was concluded    
that the release followed non- Fickian transport.  
Good correlation coefficients are obtained for Hixson Crowell cube root and Higuchi 
equation.  
The results showed that the formulation followed zero order release.  
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The present study was aimed to develop gastroretentive bilayer floating tablet 
containing Rosuvastatin Calcium as the immediate release layer using various super 
disintegrants (Sodium Starch Glycolate, Croscarmellose Sodium and Crospovidone) and 
Carvedilol as the controlled release layer using the natural (xanthan gum & Guar gum) and 
synthetic (HPMC K100) polymers. 
 Physical compatibility study showed that the drug and excipients are physically 
compatible with each other. 
 Chemical compatibility study was performed using FTIR spectroscopy and FTIR 
studies revealed that there was no change in major peaks thus confirming no 
interaction between the drug and excipients. 
 Immediate release tablets and Floating tablets were formulated by direct compression 
method. 
 The formulated blends were evaluated for precompression studies which showed that 
the flow property was good. 
 The formulated tablets were found to be within the limits with respect to uniformity of 
weight, thickness, diameter, hardness and friability. 
 The disintegration time of IR tablets containing Croscarmellose (R3) 2% was found to    
be   optimum. 
 The drug content of the formulated IR and CR tablets were found to be within the 
limits. 
 Based on the in-vitro dissolution studies of IR tablets formulation R3 (15mins) 
containing Croscarmellose was optimised and selected for final bilayer tablets. 
 Based on the in vitro dissolution studies of CR tablets, formulation C5 (24 hours) 
containing Xanthan gum (16.66%) and HPMC K100 (33.33%) was optimised and 
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selected for bilayer tablets. 
 The optimised IR (R3) and CR (C5) formulations were compressed into bilayer 
tablets. 
 The formulated bilayer tablets were found to be within the limits with respect to 
uniformity of weight, hardness, thickness, diameter and friability. 
 The drug content of the bilayer tablets were estimated by simultaneous estimation 
methodand it was found to be within the pharmacopoeial limit. 
 The in vitro dissolution studies of the optimised bilayer tablets met the IP 
specifications. 
 The release kinetics of the optimized tablets showed that it follows zero order release 
kinetics. The release of the drug from the dosage form is carried out by diffusion and 
follows Korsmeyer peppas kinetics and the n value is greater than 0.5 indicating non- 
Fickian release. 
 Bilayer tablet showed an initial burst effect (15mins) to provide dose of Rosuvastatin 
Calcium to control the blood pressure level and the controlled release of Carvedilol 
(24 hours) to reduce the cholesterol level. 
 Combination of Rosuvastatin Calcium as an immediate release layer and Carvedilol 
as a controlled release layer reduces polytherapy to monotherapy and improves the 
patient compliance. 
 The developed formulation shows an alternative to the conventional dosage form for 
the treatment of hypertension in patients. 
FUTURE PLAN 
 Scale up studies of the optimized formulation. 
 In-vivo studies and in vivo- in vitro correlation studies. 
 Bioequivalence studies with the marketed formulations. 
Bibliography 
 
Department of Pharmaceutics,Madras Medical College. Page 119 
 
1. Leon Lachman, Herbert A. Lieberman and Joseph L. Kanig. The Theory and 
practice of Industrial Pharmacy, Varghese publishing house, Mumbai; 3rd edn, 
1987: 293-5. 
2. Jain NK. Pharmaceutical Product Development. First edn. CBS Publishers. 2006; 
61-65. 
3. Swati Agarwal, Navneet Syan, Pooja Mathur. Bi-layer tablet technology- 
Opening new ways in drug delivery systems: An overview. International Journal 
of Pharmaceutical and Biomedical Sciences. 2013; 4(1); 8-15. 
4. Jain N K. Advances in controlled and novel drug delivery. New Delhi: CBS 
publisher &distributors. 2008; 4: 11- 21. 
5. Samip Shah and Shridhar Pandya. A Novel approach in gastroretentive drug 
deliverysystem: floating drug delivery system. International Journal of 
Pharmaceutical Sciences and Research. 2010; 1(6): 7- 18. 
6. Kavitha K, Sudhir Yadhav K and Tamizh Mani T. The need for floating drug 
delivery systems: a review. Research Journal of Pharmacy and Biological 
Sciences. 2010; 1(2):396-405. 
7. Chandel A. Floating drug delivery systems: A better approach, International 
Current Pharmacy Journal. 2012; 1(5): 110-8. 
8. Karthik Kumar Reddy D et al. A Review on Floating Drug Delivery System, 
World Journal of Pharmacy and Pharmaceutical Sciences. 2014; 3(7): 508-22. 
9. S. Mohideen, B. Jyothi, S. Pavani, T.Satyanarayana, P. Suresh kumar, S. 
Navaneetha Krishnan.Formulation and evaluation of bilayered tablets of 
Metformin hydrochloric deand Atorvastatin calcium. International journal of 
pharmaceutical sciences review and research.2011; 10(2): 130-134. 
10. AjitKulkarni and Manish Bhatia. Development Evaluation of Regio-selective 
Bilayer Floating Tablets of Atenolol and Lovastatin for Biphasic Release Profile. 
Iranian Journalof Pharmaceutical Research. 2009; 8(1): 15-25. 
11. Kottakranthi kumar, M. Narasimhareddy, R.Nagakishore.Formulation and 
evaluation of bilayer matrix tablet of Pioglitazone hcl Metformin 
hclusp15mg&500mg Asian Journal of Pharmaceutical and Clinical 
research.2013;6(3): 155-161. 
 
Bibliography 
 
Department of Pharmaceutics,Madras Medical College. Page 120 
 
12. Patel Geeta M. * and Patel Dinesh H. Formulation and Evaluation of Once a 
DayRegioselective Dual Component Tablet of Atorvastatin Calcium and 
Metoprolol Succinate International Journal of PharmTech Research. 2010 ;2(3) : 
1870-1882. 
13. Sanjay Dey, Sanha Chattopadhyay and Bhaskar Mazumder. Formulation and 
Evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet 
containing Atorvastatin as fast-release and Atenolol assustained-release. 
International Journal of Research in Pharmaceutical and Biomedicalsciences. 
2010; 1(2): 27-51. 
14. PreetiKarwa, P.V. Kasture. Formulation and in vitro evaluation of BilayerTablets 
of Zolpidem tartrate for Biphasic Drug. International Journal of PharmTech 
Research Release2011;3(4): 1919-1929. 
15. Kulkarani, S and Bhatia S. Design of Floating bilayer tablets of Diltiazem 
hydrochloride and Lovastatin. Parenteral Drug Association Journal of 
Pharmaceutical Science and Technology. 2008; 5: 344-52. 
16. Prabhakar Shirse. Formulation and Evaluation of Bilayer Tablets of Diclofrenac 
Sodium with Ranitidine HCL for Sustained and Immediate Release. Journal of 
Applied Pharmaceutical Science.2012;02 (05): 136-141. 
17. Ankarao A Rao, Devanna C H. Formulation and Evaluation of Bucco adhesive 
Bilayered tablets of Metoprolol Tartrate. International Journal of Research in 
Pharmaceutical and Biomedical sciences. 2010; 1(2): 67-71. 
18. Saad M. Majeed, Yehia I. Khalil. Formulation and Evaluation of bilayer matrix 
tablets of Amoxicillin and Esomeprazole as an oral modified release dosage form 
for treatment of peptic ulcer. International Journal of Pharmacy and 
Pharmaceutical Sciences. 2014;6( 3), 134-142. 
19. Anup Kumar Chakrabortya, Sudha Ranjan Mishrab, Himanshu Bhusan Sahoo. 
Formulation of Dosage Form of Rosuvastatin Calcium and Development of 
validated rp-hplc method for its estimation. International Journal of Analytical 
and Bioanalytical Chemistry 2011; 1 (3): 89-101. 
20. M.Harikrishna, Rajesh Akki, Munagala Gayatri Ramya, P.V.A.Neelimaand 
V.Vasu Naik. Formulation and evaluation of bilayerd floating tablet containing 
Carvedilol  and atenelol. Scholar Research Library. 2014; 6 (6):403-414. 
 
Bibliography 
 
Department of Pharmaceutics,Madras Medical College. Page 121 
 
21. Sreelatha.P,S.Manohar Babu,Y.Raja Jaya Rao.Formulation and evaluation of 
matrix type Rosuvastatin sustained release tablets. International Journal of 
Pharmacy and Analytical Research.2014;3(4):370-383. 
22. M.M.Gupta1, Shweta pandey, Bhupendra S.Chauhan, NirajGupta.Design, 
Development and evaluation of Rosuvastatin Calcium and Diltiazem 
Hydrochloride bilayer tablet using combination concept of sustained layer with 
conventional layer. Turkey Journal of Pharmaceutical Sciences.2014; 11(3), 269-
284. 
23. Amish V.Panchal, Markand Mehta, Viral H. Shah, Umesh Upadhyay. 
Formulation and in-vitro evaluation of muco adhesive bilayered buccal Tablets 
Of Rosuvastatin Calcium. International Jounal of Pharmaceutical Sciences and 
Research. 2012; 3(8): 2733-2740. 
24. Mahathiyelugam, Dr Koteshwara K. B, Sreenivasa reddy M. Gastro-Retentive 
floating microspheres of carvedilol: Formulation, Characterisation and in-vitro 
evaluation International Journal of Pharmacy and Pharmaceutical Sciences.2013; 
5(3): 686-690. 
25. A.Ankarao, P.Jitendrakumar,Baburao, N.Devanna and B.Venkata Phani Deepthi. 
Formulation and evaluation of bucco adhesive bilayered tablets of carvedilol. 
International Journal Of Pharmaceutical, Chemical And Biological Sciences. 
2011;1(1):6-11. 
26. M. Sujatha, R. Aruna, A.M.S Sudhakarbabu, P. Venkateswararao, 
V.Venumadhuri, M. Suvarchala. formulation and evaluation of gastro retentive 
floating tablets of carvedilol. International Journal of Research in Pharmaceutical 
and Nano Sciences.2012;1(2):170- 189. 
27. P Gajula, S Alli,P Gannu1, RK Venisetty. Design, development and evaluation of 
rosuvastatin bucco adhesive tablets. Journal of Drug Delivery 
Research.2013;2(4):1-16. 
28. Shinkar Dattatraya Manohar, Dhake Avinash Shridhar, Setty Chitral 
Mallikarjuna. Solubility and Dissolution Enhancement of Carvedilol by Solid 
Dispersion Technique Using Gelucire 50/13.International Journal of 
Pharmaceutical Sciences Review and Research.2014;29(1):161-165. 
 
Bibliography 
 
Department of Pharmaceutics,Madras Medical College. Page 122 
 
29. Omar S. Salih, Laith H. Samein and Wedad K. Ali. Formulation and In Vitro 
Evaluation Of Rosuvastatin Calcium Niosomes. International Journal of 
Pharmacy and Pharmaceutical Sciences.2013;5(4):525-535. 
30. Sowjanya Polanki, Vadithe Vasu Naik, Areti Ankarao, P V Ayodhya Neelima, 
Rajesh Akki, Munagala Gayatri Ramya.Formulation and evaluation of gastric 
floating drug delivery systems of carvedilol with natural polymers. World Journal 
Of Pharmacy and Pharmaceutical Sciences.2014; 3(2):1596-1608. 
31. Ramnath Y. Lahare, Ashish N. Phuge, Ajit L. Gite and Arjun K. Jadhav. A 
Review on Ultraviolet Spectrophotometric Determination of Rosuvastatin 
Calcium in Marketed Formulation. International Journal of Pure & Applied 
Bioscience.2014; 2 (6): 169-174. 
32. Venkata Srikanth Meka, Vanitha A/P Hong Wee Liang, Senthil Rajan 
Dharmalingham, Ravi Sheshala, Adinarayana Gorajana. Preparation and in vitro 
characterization of non-effervescent floating drug delivery system of poorly 
soluble drug, carvedilol phosphate.Journal of Acta Pharmaceutica.2014;64:485–
494. 
33. Nagesh C,Attimarad S L,Kugarji MS, Shreenal Patel, Venkatesh JS. Design and 
in-vitro evaluation of gastro retentive drug delivery system of Carvedilol. 
Universal Journal of Pharmacy.2013:02(02):118-124. 
34. Burra Shashidher and Reddy Prabakhar Veerareddy. Formulation and Evaluation 
of Carvedilol Liquisolid Tablets. African Journal of Pharmaceutical Sciences and 
Pharmacy. 2012;3(1):30-44. 
35. Rohit B Mane, Chandrakant L Bhingare, Mangesh R Bhalekar. Preparation and 
Evaluation of Carvedilol Microsphere by Spray Drying Technique: Effect of 
Process Parameters on Formulation. International Journal of Pharmaceutical 
Quality Assurance.2013; 4(1): 4-12. 
36. Pisipati Aparna, Lyadella Divya, Kalva Bhadrayya, Chavali VS 
Subrahmanyam.Formulation and In vitro Evaluation of Carvedilol Transdermal 
Delivery System Tropical Journal of Pharmaceutical Research .2013; 12 (4): 461-
467. 
 
Bibliography 
 
Department of Pharmaceutics,Madras Medical College. Page 123 
 
37. BK Garg, G. Gnanarajan, P. Kothiyal. Formulation and Evaluation of Pulsatile 
Drug Delivery System of Rosuvastatin Calcium Using Different Swelling 
Polymers. The Pharma Innovation.2012;1(12):61-67. 
38. P. Rohini. Formulation and Evaluation of Orally Disintegrating Tablets of 
Rosuvastatin. Global Journal of Pharmacology.2013;7(3): 249-257. 
39. Dhiren S. Patel, Ghanshyam R. Shah, Rajesh R. Parmar, Ashok N. Mahajan, 
Dushyant A. Shah. Simultaneous Estimation of Rosuvastatin Calcium And 
Aspirin in Pharmaceutical Dosage Form By UV Spectrophotometric Method. 
International Journal Of Institutional Pharmacy And Life Sciences.2012; 
2(2):112-121. 
40. Syed Zia UlQuasim, Abdul Naveed, Shaik Ali Abbas and Mohd Abdul Irfan. 
Formulation and Evaluation of Rosuvastatin Calcium Oral Floating Tablets. 
Research Journal of  Pharmacy and Technology.2012; 5(11):1389-1392. 
41. Chaudhari BG, Patel J. Development and Validation of Dual Wavelength 
Spectrophotometric Method for Simultaneous Estimation of Rosuvastatin and 
Diltiazem in Combined Dosage Form. International Journal for Pharmaceutical 
Research Scholars.2012;1(3):146-152. 
42. BheemeswaraRao K, Prasanna Kumar Desu, SudhakarBabu AMS, 
Venkateswarrao P. Formulation And Evaluation Of RosuvastatinImmediate 
Release Tablets . Singapore Journal of Pharmaceutical Research.2014;1(1):12-18 
43. A.Ramu,S.Vidyadhara,N.Devanna,Ch.Anusha and J. Keerthi.Formulation and 
Evaluation of Rosuvastatin Fast Dissolving Tablets. Asian Journal of 
Chemistry.2013; 25(10): 5340-5346. 
44. Ehsan Ali Mohamed, Dr.Shaimaa, N.Abd Al Hammid. Formulation And 
Evaluation Of Rosuvastatin Orodispersible Tablets. International Journal Of 
Pharmacy And Pharmaceutical Sciences. 2013;5(2):339-346. 
45. GV. Wadageri, SA. Raju, SB. Shirsand and P. Vijay Prakash Reddy. 
Development and Evaluation of Mucoadhesive Bilayer Buccal Tablets of 
Carvedilol. International Journal of Research in Pharmaceutical and Biomedical 
Sciences.2012; 3(2):576-584. 
 
 
Bibliography 
 
Department of Pharmaceutics,Madras Medical College. Page 124 
 
46. Y.Nirupa Rani, B.V.V Ravi Kumar, Smitapadma Mohanty. Development And 
Validation Of New Analytical Methods For The Estimation Of Carvedilol   In 
Bulk And Pharmaceutical Dosage. Asian Journal Of Pharmaceutical And Clinical 
Research. 2013;6(2)138-140. 
47. Anandakumar Karunakaran, VetsaSubhash, RamuChinthala, Jayamaryapan 
Muthuvijayan.Simultaneous Estimation of Rosuvastatin Calcium and Fenofibrate 
in Bulk and in Tablet Dosage Form by UV-Spectrophotometry and RP-
HPLC.Stamford Journal of Pharmaceutical sciences.2011; 4(1): 58-63. 
48. Sanjay Karla, Bharti Karla and Navneet Agarwal. Combination therapy in 
hypertension: An update Diabetology and metabolic syndrome 2010, available at 
http://www.dmsjournal.com/content/2/1/44 
49. Sunip Banerjee.Common Drug interactions incardiology prescription Medicine 
Update 2012;Vol. 22:223-228. 
50. Consumer health report Evaluating statin drugs to treat high cholesterol and heart 
diseaseavailable at: http://www.consumerreports.org/health/resources/pdf/best 
buydrugs/StatinsUpdate-FINAL.pdf. 
51. Richard E.Katholi and Daniel M.Couri. Left ventricular hypertrophy;Major risk 
factor in patients with hypertension: Update and practical clinical applications. 
52. Wikipedia.org‘dyslipidemia’availableat:http://en.wikipedia.org/wiki   
/Dyslipidemia. 
53. Merckmanuals.com‘dyslipidemia’availableat:http://www.merckmanuals.com/ 
professional/endocrine_and_metabolic_disorders /lipid_disorders /dyslipidemia. 
Html. 
54. Tripathi, K D. Essentials of medical pharmacology. New Delhi: Jaypee Brothers 
MedicalPublishers (P) Ltd. 2008; 6: 488 
55. Harrisons online: Hypertensive vascular disease; chapter 247 
56. Hypertension. Available at: http:// www.webmd. Com /hypertension 
/highbloodpressure  /guide / high-blood-pressure 
57. Peter H. Jones, MD, Michael H. Davidson, MD, Evan A. Stein et al., Comparison 
Of The Efficacy And Safety Of RosuvastatinVersus Atorvastatin, Simvastatin, 
And Pravastatin Across Doses. American  Journal Of Cardiology. 2003;93:152–
160. 
 
Bibliography 
 
Department of Pharmaceutics,Madras Medical College. Page 125 
 
58. Drugs.com. ‘Rosuvastatincalcium’.Available at:http: //www.drugs.com /ppa/ 
Rosuvastatin calcium.html 
59. DrugBank.ca. ‘Rosuvastatin calcium’. Available at : 
http://www.drugbank.ca/drugs/DB01098 
60. Indian Pharmacopoeia, Ministry of Health and Family Welfare. Ghaziabad, India: 
TheIndian Pharmacopoeia commission. 2010; 3: 2186-88. 
61. Drugs.com.‘Carvedilol’.Available at : http://www.drugs.com/ppa/Carvedilol.html 
62. British Pharmacopoeia. Medicines and Healthcare products Regulatory Agency. 
London:The Stationery Office. 2009; I: 5872- 77 
63. DrugBank.ca.‘Carvedilol’.Available at : http://www.drugbank.ca/drugs/DB01136 
64. United States Pharmacopoeia, 30th edition NF 25-2007. The Official Compendia 
of Standards. 643, Pharmacopoeial forum 32(1): 141 
65. Raymond C et al. Hand Book of Pharmaceutical Excipients. London: 
PharmaceuticalPress and American Pharmacists Association. 2009. 129-131, 190, 
208-9, 262-4, 326-8,346-8, 400-1, 404-6, 581, 629-32, 658, 663-5, 703-6, 728, 
782-4. 
66. Gurdeep R Chatwal and Sham K Anand. Instrumental methods of Chemical 
Analysis.Himalaya Publishing House, Mumbai. 2011; 2.44. 
67. Rishikeshet al. Contemporary Approaches for Bi-Layer Technology of Drugs 
ThroughOral Route: An Overview. International Journal of Pharmaceutical 
Sciences andResearch. 2013; 4 (4): 1326-1334. 
68. Beckett A H and Stenlake J B. Practical Pharmaceutical Chemistry. CBS 
Publishers andDistributors, New Delhi. 4th edn. 2007: 284-6. 
69. ChandrasekaraRaoBaru, S. Vidhyadhara, K.V RaghavendraRaoet al. Formulation 
and evaluation of ibuprofen floating tablets. International Journal of 
Pharmaceutical, Chemical and Biological Sciences, 2012; 2(4); 472-81.  
70. Suvakanda Dash, PadalaNarasimha Murthy, LilakantaNath and 
PrasantaChowdhary.Kinetic modeling on drug release from controlled drug 
delivery systems. ActaPoloniaePharmaceutica. Drug research.2010; 67(3): 217-
23 
71. Suresh Karudampala, Gnanaprakash K, Venkadesh B et al. Formulation and 
evaluation of gastro retentive floating bilayer tablets of Nifidipine. American 
Journal of Advanced Drug Delivery. 2013; 1(3); 341-57. 
Bibliography 
 
Department of Pharmaceutics,Madras Medical College. Page 126 
 
 
72. P H Wakde, Kasliwal R H and Mane S B. Design and fabrication of 
gastroretentivebilayer floating tablet of PropronololHCl using natural polymer; 
International Journal ofPharmaceutical Sciences and Research. 2013; 4(12): 
4715-28. 
73. Dayakarreddy B, Saikishore V, TejaKrishna M et al. Preparation and evaluation 
of levofloxacin hemihydrates floating tablets. Journal of Drug Delivery and 
Research.2013; 2(1); 1-15.  
74. Pranaj Kumar Singh, Sanjoo Kumar, V K Shuklaet al. Bilayer and floating- 
bioadhesive tablets: Innovative approach to gastroretention. Journal of Drug 
Delivery and Therapeutics. 2011; 1(1); 32-5.  
75. Swati M. Auteet al. Novel Approach in Gastro Retentive Drug Delivery 
System:Floating Microspheres. International Journal of Pharmaceutical and 
Biological ScienceArchive. 2014; 2 (5): 09-22. 
76. Suvakanda Dash, PadalaNarasimha Murthy, LilakantaNath and 
PrasantaChowdhary.Kinetic modeling on drug release from controlled drug 
delivery systems. ActaPoloniaePharmaceutical. Drug research.2010; 67(3):     
217-23. 
 
 
